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 Epilepsy describes a spectrum of common and devastating neurological disorders 
characterized by recurrent unprovoked seizures.  Approximately 70% of epilepsy patients 
achieve seizure freedom with the use of clinically available antiseizure drugs, while the 
remaining 30% of patients are considered drug-resistant.  It has been proposed that in 
order to effectively treat drug-resistant patients, future research must focus on novel 
molecular targets that are capable of modifying the underlying pathology of epilepsy.  
 Potential novel targets include the neuropeptide galanin and its cognate receptors.  
Hippocampal galanin expression is increased following seizure activity and 
experimentally increasing central galanin produces antiseizure activity in a number of 
animal models.  However, the specific role of the galanin receptors (GalR1-3) in 
mediating the anti-seizure properties of galanin remains unclear.  To address this issue a 
collaboration was established between the laboratories of Drs. H. Steve White and 
Grzegorz Bulaj to design, synthesize, and characterize novel, receptor-preferring, 
galanin-based neuropeptides.  One analog generated from these studies, NAX-5055, 
displays a 15-fold preference for the GalR1 receptor and potent antiseizure activity in a 
battery of seizure and epilepsy models. 
 The overall goal of this dissertation was to further characterize the properties of 
NAX-5055.  Electrophysiological studies evaluated the mechanism of action of NAX-




release in the CA3 region of the hippocampus.  Interestingly, behavioral studies 
demonstrated that the antiseizure efficacy of NAX-5055 was markedly reduced following 
repeated systemic administration.  As a result, we investigated the potential 
mechanism(s) that could account for this observation.  Our studies suggest that the 
reduced efficacy of NAX-5055 is not likely due to an alteration in galanin receptor 
function, efflux transport by P-glycoprotein, or increased peripheral metabolism. 
 The studies presented in this dissertation were able to rule out several candidate 
mechanisms for the reduced efficacy of NAX-5055; however, additional work will be 
required to fully understand this phenomenon.  In addition, our functional studies provide 
the first indication that galanin can decrease hippocampal excitability through a 
presynaptic mechanism.  Future studies with NAX-5055 will increase our understanding 
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 Neuropeptides are a large group of signaling molecules expressed throughout the 
central and peripheral nervous systems.  Following repetitive neuronal stimulation, 
neuropeptides can be released into the extracellular space and modulate surrounding 
synaptic activity through interaction with pre- and post-synaptic G-protein-coupled 
receptors.  The modulatory activity of these molecules has been implicated in the 
pathophysiology of a number of neurological disorders that include epilepsy, Alzheimer’s 
disease, and neuropathic pain.  As a result there has been significant interest in the 
development of neuropeptide-based therapeutics (Malavolta and Cabral, 2011; Robertson 
et al., 2011).  In the following dissertation, I describe the functional and behavioral 




Epilepsy and Therapeutic Intervention 
 
Epilepsy affects more then 50 million people worldwide; making it one of the 
world’s most common neurological disorders (WHO, 2007).  Within the United States, 
there are approximately 2.2 million people living with epilepsy and an estimated 150,000 
new cases diagnosed annually (Hirtz et al., 2007; Institute of Medicine, 2012).  Epilepsy 
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is characterized by the development of spontaneous recurrent seizures, which can 
manifest in a variety of electrical and behavioral phenotypes.  In general, seizures can be 
defined as temporally distinct, paroxysmal ictal discharges within specific (i.e., focal 
seizure) or widespread brain regions (i.e., generalized seizure) (D'Ambrosio and Miller, 
2010).  The neuroanatomical location of the seizure focus can vary in patients with 
different seizure disorders.  For example, in temporal lobe epilepsy, a common seizure 
disorder, the seizure focus is often found in the hippocampus which can be characterized 
by hippocampal sclerosis, and can often by treated by the resection of this brain region 
(Falconer, 1974; Engel, 1996; Engel et al., 2003).  As a result, clinical and experimental 
epilepsy research has centered its attention on the hippocampus as a region of interest to 
understand the pathology of epilepsy and to test potential therapeutic interventions 
(O'Dell et al., 2012). 
Drugs administered for the treatment of epilepsy have classically been defined as 
antiepileptic drugs (AED).  However, many of these drugs only inhibit seizure activity 
without affecting the overall progression of the disease state.  As a result these drugs are 
more correctly termed anti-seizure drugs (Galanopoulou et al., 2012).  The term 
antiepilepsy therapy has thus been reserved for drugs that prevent or delay the 
progression of epilepsy (Galanopoulou et al., 2012).  To date, there are no dugs clinically 
available that are considered true antiepilepsy therapies. 
There are currently over 20 antiseizure drugs available with varying mechanisms 
of action.  These include drugs that decrease neuronal excitability through inhibition of 
voltage-gated Na+ channels or increase inhibitory tone through augmentation of 
GABAergic neurotransmission.  These drugs continue to provide the clinician and patient 
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with a broad range of treatment options (Bialer and White, 2010).  Pharmacological 
treatment with antiseizure drugs results in seizure freedom for approximately 70% of 
epilepsy patients; many are effectively controlled by mono-therapy (Stephen and Brodie, 
2012).  However, the remaining 30% of epilepsy patients do not achieve full therapeutic 
control of their seizures and are thus considered therapy resistant (Löscher and Schmidt, 
2011).  Therapy-resistant epilepsy is clinically defined as a failure to achieve seizure 
control following treatment with two well-tolerated, appropriately chosen anti-seizure 
drugs administered as mono-therapy or in combination (Kwan et al., 2010).  Surgical 
intervention provides an additional and effective treatment option for some drug-resistant 
patients, but requires the identification of a clear seizure focus that can be easily resected 
(Engel, 1996; Engel et al., 2003).  As a result, there remains a significant population of 
therapy-resistant epilepsy patients who are not candidates for surgical resection and are 
thus left with limited options for the treatment of their seizures (Cascino, 2008).  It has 
been suggested that in order to help these patients, the focus of therapeutic intervention 
should shift toward modulation of the pathological brain, not simply decreasing neuronal 
excitability (Löscher and Schmidt, 2011).  Thus, there has been considerable interest in 
novel molecular targets aimed at modulating pathological synaptic transmission. 
 
 
Neuropeptides as Drug Targets for Epilepsy 
 
 The neuropeptides and their receptors present interesting targets for the 
development of novel therapeutic interventions for patients with epilepsy (Robertson et 
al., 2011).  Neuropeptides are a class of signaling molecules distinct from classical 
neurotransmitters in size, synthesis, and mechanism of action.  Neuropeptides are 
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synthesized from larger precursor proteins in the cell soma and packaged into dense core 
vesicles (DCV) that require axonal transport to reach presynaptic terminals.  Modulation 
of neuropeptide levels within the presynaptic terminal is relatively slow (i.e., minutes to 
hours) and requires changes in gene expression and additional DCV trafficking.  Unlike 
synaptic vesicles, DCV release is not restricted to the active zone of the presynaptic 
terminal.  Furthermore, neuropeptides are not released following single action potential 
depolarization-induced increases in Ca2+ microdomains at the active zone.  Thus, during 
periods of low neuronal firing, neuropeptides have little influence on synaptic activity.  
However, high frequency neuronal firing, similar to that observed during seizure activity, 
increases Ca2+ levels throughout the presynaptic terminal to concentrations sufficient to 
induce DCV vesicle fusion and neuropeptide release.  Neuropeptide signaling is mediated 
by volume transmission thus allowing for modulation of synaptic activity in a large area 
surrounding the site of release.  In addition, neuropeptides are not subject to active 
reuptake, but rather are inactivated enzymatically or by diffusion.  This results in a 
relatively long duration of activity.  Thus, the neuropeptides are well suited to facilitate or 
inhibit highly active neuronal circuits.  Indeed, following intense seizure activity, a 
number of neuropeptides, including galanin, neuropeptide Y and somatostatin, are 
released within the hippocampus and act to facilitate or inhibit seizure activity (Robertson 
et al., 2011).  The work presented in this dissertation is focused on the anti-seizure 









Galanin Regulation of Seizure Activity 
 
 Galanin is a 29 (30 in humans) amino acid neuropeptide originally isolated from 
the porcine intestine (Tatemoto et al., 1983).  It displays extensive expression in the 
central, peripheral, and enteric nervous system (Melander et al., 1986).  The first 15 N-
terminal amino acids of galanin are highly conserved between species, including humans 
(Evans and Shine, 1991).  Galanin is synthesized by proteolytic processing of the 123-
amino acid preprogalanin precursor protein (Kofler et al., 1996).  Along with galanin, a 
59-amino acid peptide known as galanin message associated peptide (GMAP) is 
synthesized. Unlike galanin, GMAP does not display binding affinity for any of the 
known galanin receptors (Rökaeus and Brownstein, 1986; Lang et al., 2007). 
 The first suggestion that galanin could regulate seizure activity was the 
demonstration of its expression within the hippocampal formation; a common seizure 
focus in temporal lobe epilepsy patients.  There are two major galanin-containing 
projections that innervate the hippocampus; one a noradrenergic projection originating 
from the locus coeruleus and the second a cholinergic projection originating in the 
septum/diagonal band complex (Melander et al., 1986; Consolo et al., 1994; Xu et al., 
1998).  These galanin-containing projections extend throughout the hippocampal 
formation, but appear particularly robust in the ventral regions (Yoshitake et al., 2011).  
Galanin projections are also of particularly high density within the dentate gyrus 
(Mazarati, 2004).  This is an interesting observation given that the dentate gyrus is 
thought to serve as a gate for the propagation of seizure activity within the hippocampus 
(Heinemann et al., 1992; Coulter and Carlson, 2007).  It is also interesting to note that de 
novo neuronal galanin expression is observed following seizure activity in the hilar 
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region of the dentate gyrus (Mazarati et al., 1998).  It has been hypothesized that 
upregulation of galanin in the hilar region is specific to interneurons and occurs as an 
compensatory anti-seizure response (Mazarati et al., 1998).  Although this is an intriguing 
hypothesis, further testing is required to confirm these observations. 
 Mazararati et al. (1992) were the first to provide direct evidence that galanin 
could inhibit seizure activity in the brain.  In their studies, galanin was shown to decrease 
the severity of picrotoxin-kindled seizures in rats following bilateral injection (50-200 
ng) into the lateral ventricles (Mazarati et al., 1992).  Later, the same group provided 
compelling evidence of the antiseizure properties of galanin specifically within the 
hippocampus.  Their studies utilized perforant path stimulation and Li-pilocarpine models 
of status epilepticus (SE) in which animals experienced a prolonged bout of severe 
seizure activity followed by the development of spontaneous seizures.  Direct injection of 
galanin (0.5 nmol) into the hilar region of the dentate gyrus inhibited the induction of SE 
and blocked seizure activity in rats with previously established SE (Mazarati et al., 1998).  
Further, the effects of galanin on SE were attenuated by the nonselective galanin receptor 
antagonist M35 (Mazarati et al., 1998).  Immunohistochemical evaluation of the 
hippocampus following SE illustrated that galanin staining is nearly abolished three hours 
after the initiation of seizure activity; suggesting exhaustion of galanin stores (Mazarati et 
al., 1998; Lerner et al., 2008). 
 Under normal physiological conditions galanin, like many peptides, is degraded 
by endogenous peptidases once it is released, making it difficult to study the function of 
long-term activation.  As a result, a number of investigators have generated genetically 
modified mice that show increased or decreased galanin expression.  Overexpression of 
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galanin, under the dopamine-!-hyroxylase promoter, attenuated the severity of SE 
induced by either perforant path stimulation or the glutamate agonist kainic acid (KA) 
(Mazarati et al., 2000).  More widespread overexpression of galanin was achieved using 
the platelet-derived growth factor B (PDGF) promoter and resulted in delayed kindling 
acquisition in both mice and rats (Kokaia et al., 2001; Schlifke et al., 2006).  In contrast, 
in galanin knockout mice the seizure phenotype was exaggerated, such that animals were 
more susceptible to seizure induction and cell death (Kerr et al., 2000; Mazarati et al., 
2000). 
 The success of maintaining the antiseizure properties of galanin through genetic 
overexpression has made galanin a target for the development of gene therapy 
approaches.  A number of elegant studies have utilized adeno-associated virus (AAV) 
vectors to increase central galanin levels.  The first of these studies used a fibronectin 
secretory sequence (FIB) to ensure the active secretion of galanin into the extracellular 
space (Haberman et al., 2003).  Injection of AAV-FIB-galanin into the inferior colliculus 
attenuated seizures following electrical stimulation, whereas injection into the piriform 
cortex attenuated seizures induced by KA treatment (Haberman et al., 2003; McCown, 
2006).  Utilizing the neuron-specific promoter neuron specific enolase (NSE), direct 
injection of AAV-NSE-galanin into the dentate gyrus blocked the development of 
seizures following an intrahippocampal KA injection (Lin et al., 2003).  AAV-NSE-
galanin was also shown to delay the progression of kindled seizures by slowing the 
development of kindling; a finding consistent with that observed following 
overexpression with PDGF (Kanter-Schlifke et al., 2007).   
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 One proposed mechanism for the antiseizure activity of galanin is the inhibition of 
neurotransmitter release.  Incubation of transverse hippocampal brain slices with galanin 
inhibits the release of glutamate and aspartate following a depolarizing stimulation (Zini 
et al., 1993).  Similar studies have been conducted utilizing transgenic mice.  In 
hippocampal slices taken from mice overexpressing galanin with the dopamine-!-
hydroxylase promoter, a significant reduction in the release of glutamate following slice 
depolarization was observed (Mazarati et al., 2000).  However, in hippocampal slices 
taken from galanin-knockout mice a significant increase in glutamate release following 
slice depolarization was reported (Mazarati et al., 2000).  Although these studies strongly 
suggest that galanin is an effective regulator of hippocampal excitability, it still remains 
unclear what cellular mechanisms mediate the observed inhibition of glutamate release. 
 
 
Role of Galanin Receptors in Seizure Regulation 
 
 There have been three galanin receptors cloned to date, GalR1-3; all belong to the 
G-protein coupled receptor super family.  All three receptor subtypes are expressed in the 
brain, but only GalR1 and GalR2 have been shown to be expressed in the hippocampus.  
It is still unclear how each receptor mediates the anti-seizure activity of galanin.  
Understanding the localization of the galanin receptors has relied heavily on the use of in 
situ hybridization and autoradiography due to unreliable antibodies and limited receptor-










 The human GalR1 receptor was originally cloned from the Bowes melanoma cell 
line; whereas the rat version of the GalR1 receptor was cloned from rat brain and Rin13B 
insulinoma cells (Habert-Ortoli et al., 1994; Burgevin et al., 1995; Parker et al., 1995).  
There is 92% similarity between the human, rat, and mouse GalR1 receptor homologs 
(Jacoby et al., 1997; Branchek et al., 2000).  The GalR1 receptor is expressed throughout 
the body, including the gastrointestinal tract, pancreas, brain, and spinal cord (Gustafson 
et al., 1996; Pham et al., 2002; Hohmann et al., 2003; Barreto et al., 2011).  Within the 
brain, the expression pattern is broad and includes the amygdala, lateral septum, ventral 
hippocampus, and thalamus (Gustafson et al., 1996; Hohmann et al., 2003; Jungnickel 
and Gundlach, 2005).  When expressed in immortalized cell lines GalR1 has been shown 
to inhibit forskolin-stimulated cAMP release, open G-protein-coupled inwardly rectifying 
(GIRK) channels, and stimulate mitogen-activated protein kinase (Habert-Ortoli et al., 
1994; Parker et al., 1995; Smith et al., 1998; Wang et al., 1998b).  These intracellular 
pathways are all inhibited in the presence of pertussis toxin; suggesting that the GalR1 
receptor selectively couples to a Gi-type G-protein.  Following receptor activation in 
immortalized cell lines, GalR1 receptors are internalized in a clathrin-dependent manner 
(Wang et al., 1998a; Xia et al., 2008).  Once internalized, receptors are trafficked to 
lysosomes for degradation, which is dependent on a C-terminal signal motif, suggesting a 






 The second cloned galanin receptor (GalR2) was first cloned in the rat 
hypothalamus, GalR2 homologs has also been cloned for both mouse and human (Smith 
et al., 1997; Pang et al., 1998; Fathi et al., 1998a).  There is a high level of homology 
between the GalR2 receptor across species, but only 40% homology with rat and human 
GalR1 (Howard et al., 1997; Wang et al., 1997).  The mRNA expression pattern of GalR2 
is also quite broad; appearing in almost all tissues including the brain and spinal cord 
(Branchek et al., 2000).  Within the brain, the GalR2 receptor is expressed in many of the 
same areas as GalR1 including the amygdala and hippocampus.  GalR2 is also found in 
the hypothalamus and the dentate gyrus (Fathi et al., 1998b; O'Donnell et al., 1999).  
Unlike GalR1 receptors, the GalR2 receptor has been suggested to interact with multiple 
G-proteins that may utilize different intracellular cascades.  The most commonly reported 
effect of GalR2 is the activation of phospholipase C (PLC).  This results in the release of 
intracellular Ca2+ stores and the opening of calcium-dependent chloride channels (Fathi et 
al., 1997; Smith et al., 1997; Pang et al., 1998).  Activation of this pathway may also 
result in the inhibition of caspase-3 and caspase-9; effects that may account for the 
neuroprotective effects of galanin that have been attributed to activation of GalR2 
(Hobson et al., 2006; Elliott-Hunt et al., 2007; 2011).  These intracellular effects were not 
affected by pertussis toxin; suggesting an interaction with the Gq/11-type G-protein.  The 
interaction of GalR2 with the Gi-type G-protein has remained controversial; i.e., some 
studies have shown an inhibition of forskolin-stimulated cAMP accumulation, whereas 
others have been unable to repeat these effects in similar cell lines (Fathi et al., 1997; 
Smith et al., 1997; Wang et al., 1997).  In those studies that observe an inhibition of 
  
11 
cAMP accumulation, the effects are pertussis toxin-sensitive, thereby suggesting a 
potential coupling of GalR2 to the Gi-type G-protein (Wang et al., 1997).  Following 
activation, GalR2 receptors, like the GalR1 receptors, are internalized.  However, once 
internalized the receptor rapidly recycles back to the cell membrane following galanin 
washout (Xia et al., 2005; Lu et al., 2005c). 
 
 
Galanin Receptor Regulation of Seizure Activity 
 
 The study of galanin receptor subtype specificity of the anti-seizure effects of 
galanin has been limited somewhat by the lack of receptor-selective pharmacology.  As a 
result, much of what we know about galanin receptors in regulating seizure activity has 
come from studies with genetically modified mice.  The GalR1 knockout mouse was 
generated on a C57BL/6J background (Jacoby et al., 2002).  It has been documented that 
some of these mice display spontaneous seizures; although this has not been reported in 
all studies utilizing these mice (Jacoby et al., 2002; Mazarati et al., 2004b; McColl et al., 
2006).  Mazarati et al. demonstrated that the cumulative time spent in seizures and the 
single seizure duration were increased in GalR1 knockout mice when SE was induced by 
Li-pilocarpine or perforant path stimulation, but not KA administration (Mazarati et al., 
2004b; Schauwecker, 2010).  However, significant neuronal loss was observed in CA1, 
CA2 and the hilus of GalR1 knockout mice following systemic KA administration.  This 
finding suggests that the GalR1 receptor may also be involved in cell survival 
(Schauwecker, 2010).  Partial transient knockdown of the GalR2 receptors in the 
hippocampus utilizing peptide nucleic acid antisense oligonucleotides resulted in an 
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(Mazarati et al., 2004a).  However, in a full GalR2 knockout mouse there was no 
difference in seizure susceptibility following either pentylenetetrazole (PTZ) or flurothyl 
induced seizures (Gottsch et al., 2005).  Based on these studies, it seems likely that both 
GalR1 and GalR2 are involved in regulating seizure susceptibility; however additional 




Galanin-Receptor Interactions and Pharmacology 
 
 Site-directed mutagenesis studies have illustrated a series of critical residues 
facilitating the interaction of galanin with its receptors.  For the GalR1 receptor, the 
major interactions between receptor and peptide were found to be His264 and His267 
toward Trp2, Phe292 toward Try9, and Phe115 toward Gly1 (Berthold et al., 1997; Church et 
al., 2002).  Studies utilizing the non-GalR1 selective galanin fragment, Gal (2-11) (AR-
1896), have identified the key residues facilitating the GalR2-agonist interaction.  These 
residues include His252, His253, Ile256, Phe264, and Tyr271 on the GalR2 receptor and Trp2, 
Asn5, Gly8, Tyr9, and Leu10 on the peptide fragment (Lundström et al., 2005; 2007).  A 
number of galanin chimeric peptides and galanin fragments have been generated and 
characterized.  The chimeric peptides including C7, M15, M32, M35, and M40 all 
maintain nanomolar binding affinity for galanin receptors and demonstrate antagonistic 
activity (Lang et al., 2007).  The full rat galanin, Gal(1-29) and the N-terminal fragment 
Gal(1-16) demonstrate a slight preference for the GalR1 receptor.  The full peptide 
displays a slightly higher binding affinity.  Both full length galanin and Gal(1-16) also 
display anticonvulsant activity following intracerebroventricular (i.c.v.) injection (Lang 
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et al., 2007).  Perhaps the most useful galanin fragment characterized to date is Gal (2-11) 
(AR-1896).  This particular peptide displays no appreciable affinity for the GalR1 
receptor and as such provides a useful pharmacological tool to isolate the activity of 
GalR2/3 receptors (Lu et al., 2005a).   
 In addition to these galanin fragments and chimeras two small-molecule receptor 
ligands have been synthesized: galmic and galnon (Saar et al., 2002).  Galnon displaces 
I125-galanin in rat ventral hippocampus and inhibits forskolin-stimulated cAMP 
accumulation (Saar et al., 2002).  Systemic injection of galnon was found to abolish PTZ-
induced seizures in mice; whereas intrahippocampal administration decreased the 
duration of perforant path-stimulated SE (Saar et al., 2002).  Galmic displays micromolar 
binding for only GalR1 and attenuates perforant path-stimulated SE following both 
systemic and intrahippocampal administration (Bartfai et al., 2004).  Despite the benefits 
of a large number of pharmacological tools many of these compounds are only effective 
following central administration because they are susceptible to rapid enzymatic 
degradation and lack the ability to penetrate the blood brain barrier.  Those that are active 
systemically have relatively low binding affinity.  Furthermore, both galmic and galnon 
display off target activity within their effective concentration range (Lu et al., 2005b).   
 Bulaj et al. (2008) utilized a combination of cationization and lipidization 
approaches in an effort to generate a new series of systemically available galanin analogs.  
The lead analog from these studies, NAX-5055, maintains the Gal(1-13) core of the 
endogenous galanin peptide with the addition of a palmitoyl fatty acid tail attached to a 




Figure 1.1. Chemical structure and binding properties of the novel galanin analog, NAX-
5055 
 
A) Diagram of the chemical structure of NAX-5055 illustrating the backbone galanin 
fragment, Gal (1-13), as well as the cationization and lipidization modifications added to 
increase bioavailability. 
 
B.) Time resolved fluorescence competition binding assays of NAX-5055 (") or the 
galanin fragment Gal (1-16) (☐) incubated with europium tagged galanin (1-29).  
Binding affinity (Ki) for both Gal (1-16) and NAX-5055 are in the nanomolar range for 
both GalR1 and GalR2 receptors.  Comparison of binding affinity for both galanin 
receptors demonstrates a 15-fold preference of NAX-5055 for GalR1.  Adapted from 










































































NAX-5055 displays nanomolar affinity for both galanin receptors with a 15-fold 
preference for GalR1 (i.e. 3.5 nM for GalR1 and 51.5 nM for GalR2) (Figure 1.1B), and 
demonstrates an increased half life of approximately 10 hrs in an in vitro rat serum assay 
(Bulaj et al., 2008).  When administered systemically, NAX-5055 displays minimal 
motor toxicity and exhibits potent anticonvulsant activity in a battery of animal seizure 
and epilepsy models (Bulaj et al., 2008; White et al., 2009).  This analog thus provides a 






 The goal of this dissertation was to characterize the mechanism of action and anti-
seizure properties of the novel galanin analog NAX-5055.  The work presented in 
Chapter 2 begins to elucidate the functional activity of NAX-5055 within the 
hippocampus.  We used whole-cell patch clamp recordings of miniature excitatory 
postsynaptic currents (mEPSCs) to test the hypothesis that NAX-5055 decreases 
hippocampal excitability by reducing presynaptic glutamate release.  To our knowledge 
this is the first study to delineate between pre- and post-synaptic mechanisms of a 
galanin-based neuropeptide. 
 The second aim of this work was to determine if NAX-5055 was capable of 
delaying the development of kindled seizures in a manner similar to what has been 
reported in galanin-overexpressing mice and rats (Kokaia et al., 2001; Kanter-Schlifke et 
al., 2007).  If NAX-5055 could inhibit or delay kindling acquisition, and thus limit 
disease progression, this peptide could be considered to possess important anti-seizure 
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and disease modifying properties.  However, as presented in Chapter 3, NAX-5055, 
under the conditions tested, did not affect the acquisition of corneal kindling.  This result 
was unexpected and led to the question of what effect repeated administration of NAX-
5055 might have on the efficacy of this peptide.  Further studies in the 6 Hz psychomotor 
seizure model demonstrated that following repeated administration, the anti-seizure 
efficacy of NAX-5055 was markedly reduced. 
 I evaluated three different hypotheses that could account for the dramatic 
reduction in efficacy of NAX-5055 following repeated systemic administration.  The first 
two hypotheses are discussed in detail in Chapter 3. The first hypothesis proposes that 
central galanin receptors display decreased availability for interaction with NAX-5055 as 
a result of receptor internalization or decreased sensitivity.  The second hypothesis 
proposes that the efflux transport of NAX-5055 is increased such that therapeutic brain 
levels are no longer attained.  The third and final hypothesis is discussed in Chapter 4 and 
proposes that an increase in peripheral metabolism of NAX-5055 may reduce the amount 
of functional peptide available for interaction with central galanin receptors. 
 The studies presented in this dissertation do not provide a clear mechanism 
underlying the reduced efficacy following multiple dosing with NAX-5055.  However, 
this work outlines a series of in vivo and in vitro assays that will be useful in future 
characterization and validation of the clinical utility of neuropeptide-based theraputics.  
Together, the studies presented in this dissertation open more questions than they answer, 
but lay the groundwork for the use of NAX-5055 and other galanin analogs to increase 
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MODULATION OF HIPPOCAMPAL EXCITATORY SYNAPTIC  





 Galanin is a 29 amino acid endogenous neuropeptide with a broad expression 
pattern within the central and peripheral nervous systems that has been suggested to 
protect against pathological changes in a number of neurological disorders.  There are 
three cloned galanin receptors, GalR1, 2 and 3 that all belong to the G-protein family of 
receptors.  It has been suggested that galanin modulates neuronal excitability within the 
hippocampus by reducing the probability of glutamate release.  However, it is unclear 
how each receptor subtype mediates this physiological activity of galanin.  We have 
recently designed a systemically active, metabolically stable GalR1-preferring galanin 
analog, NAX-5055.  In this study we sought to determine if NAX-5055 could reduce 
hippocampal excitatory synaptic transmission by inhibiting presynaptic glutamate release 
onto CA3 pyramidal neurons.  We demonstrate in mouse organotypic hippocampal slice 
cultures that NAX-5055 (500 nM) increases the inter-event interval of miniature 
excitatory postsynaptic currents (mEPSC) in CA3 pyramidal cells without having any 
effect on the amplitude of these events.  These findings suggest that activation of GalR1 
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receptors on presynaptic glutamatergic terminals in CA3 results in a decrease in the 
probability of glutamate release from these terminals.  This is the first physiological 
evidence suggesting that GalR1 receptors are located on presynaptic glutamatergic 
terminals in CA3 and that this receptor subtype can modulate presynaptic glutamate 
release.  NAX-5055 provides an interesting tool to further understand how galanin 
receptors modulate synaptic transmission.  Further studies with NAX-5055 will help 




 Galanin is a 29 (30 in humans) amino acid neuropeptide that displays a broad 
expression pattern within the central and peripheral nervous systems (Tatemoto et al., 
1983; Lang et al., 2007).  Interest in elucidating a detailed mechanism of action for 
galanin stems from its known modulatory effects on a number of neurological 
phenomena including neuronal excitability, neuroendocrine regulation, neuronal 
development, and cell survival (Hobson et al., 2008; Lerner et al., 2008; Mechenthaler, 
2008).  These physiological actions of galanin have been demonstrated to serve important 
roles in the endogenous response of the central nervous system to neurological disorders 
such as epilepsy, Alzheimer’s disease, neuropathic pain, and mood disorders (Lundström 
et al., 2005; Wiesenfeld-Hallin et al., 2005; Crawley, 2008; Lerner et al., 2008; Rotzinger 
et al., 2010). 
 Galanin’s ability to modulate neuronal excitability may be particularly relevant 
within the hippocampal formation, a region known to be prone to seizure generation.  
Within the hippocampus, galanin is expressed in efferent cholinergic and noradrenergic 
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fibers originating in the medial septum/diagonal band and locus coeruleus, respectively 
(Melander et al., 1986; Gabriel et al., 1995; Xu et al., 1998).  There are three known 
galanin receptors (GalR1, 2, and 3) that all belong to the G-protein coupled receptor 
family (Habert-Ortoli et al., 1994; Parker et al., 1995; Smith et al., 1997) and [125I]-
galanin binding and in situ hybridization studies have demonstrated moderate to high 
expression levels of both GalR1 and GalR2 receptors within the hippocampus.  GalR1 
receptors are expressed throughout the corna ammonis (CA) fields of the ventral 
hippocampus, while GalR2 receptors are highly expressed in the dentate gyrus and 
display more moderate expression in the CA fields (Burgevin et al., 1995; O'Donnell et 
al., 1999; Lu et al., 2005b).  Thus the neuroanatomical organization of the galanin system 
is well positioned to modulate hippocampal activity.  Unfortunately, the lack of specific 
commercially available antibodies to the galanin receptors has made it difficult to 
confirm cell type specific protein expression (Lu and Bartfai, 2009). 
 Within the CNS, galanin is coexpressed with a number of classical 
neurotransmitters including acetylcholine, catecholamines, and serotonin and is thought 
to inhibit the release of these neurotransmitters during periods of high neuronal activity 
(Melander et al., 1986; Fisone et al., 1987; Tallent, 2008).  These effects on 
neurotransmitter release are believed to occur though galanin receptor-mediated 
modulation of ATP-dependent K+ channels, G-protein inwardly rectifying K+ (GIRK) 
channels or voltage-gated Ca2+ channels (Palazzi et al., 1991; Zini et al., 1993; Jacoby et 
al., 2002; Kerekes et al., 2003; Endoh et al., 2008; Anselmi et al., 2009).  Within the 
hippocampal formation, activation of galanin receptors by the active galanin fragment 
Gal(1-16) resulted in a 50% reduction of both glutamate and aspartate release following a 
  
27 
depolarizing stimulation (Zini et al., 1993).  Further, in similar experiments performed 
with mice overexpressing galanin selectively in noradrenergic fibers, glutamate release 
was also significantly reduced following hippocampal slice depolarization.  In contrast, in 
hippocampal slices acquired from galanin knockout mice, glutamate release is nearly 
doubled following the same depolarizing stimulation (Mazarati et al., 2000).   
 The robust inhibitory effects of galanin on the release of glutamate release in the 
hippocampus have lead to more rigorous electrophysiological analysis of this activity.  At 
the mossy fiber-CA3 synapse in hippocampal slices, galanin overexpression resulted in a 
lowered frequency facilitation of the excitatory postsynaptic field potential (fEPSP), a 
form of short-term plasticity.  This change in frequency facilitation was inhibited by the 
non-selective galanin antagonist M35 in the same galanin-overexpressing mice, 
confirming that this effect was mediated by galanin receptors (Kokaia et al., 2001).  
Galanin has also been shown to impair CA1/CA3 long term potentiation (LTP) in acute 
hippocampal slices, as well as dentate gyrus LTP both in hippocampal slice and in vivo 
(Coumis and Davies, 2002; Badie-Mahdavi et al., 2005b; Kinney et al., 2009).  Taken 
together these data strongly support a role for galanin in the regulation of hippocampal 
excitatory synaptic transmission.   
 Within the hippocampal formation, galanin expression is highly plastic in 
response to experimentally induced seizure activity.  Following status epilepticus induced 
by either Li-pilocarpine or perforant path stimulation, galanin immunoreactivity is 
drastically reduced in efferent fibers within 30 min.  However, within 24 hr after status 
epilepticus or hippocampal kindling there is de novo expression of galanin mRNA in the 
dentate gyrus (Mazarati et al., 1998; Kokaia et al., 2001).  In animals overexpressing 
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galanin, high levels of expression are observed in the dentate granuale cell layer, and this 
pattern of expression is enhanced and extended into the mossy fiber projection following 
hippocampal kindling (Kokaia et al., 2001; Lin et al., 2003; Kuteeva et al., 2005). 
 It remains unclear how the two galanin receptors mediate the effects of galanin on 
hippocampal excitatory synaptic transmission or seizure activity.  Similar to many 
neuropeptide receptors, the GalR1 receptor selectively couples to the Gi-type G-protein, 
reducing cAMP through inhibition of adenylyl cyclase, opening GIRK channels, and 
stimulating mitogen-activated protein (MAP) kinase activity (Branchek et al., 2000; Lang 
et al., 2007).  These intracellular functions suggest that the GalR1 receptor is well suited 
to regulate neuronal excitability.  In contrast, the GalR2 receptor displays a more 
complicated signaling cascade, and it is capable of interacting with numerous G-proteins.  
The most commonly observed pathway involves the activation of phospholipase C 
(PLC), which results in the release of Ca2+ from intracellular stores and opening Ca2+-
dependent chloride channels that are potentially mediated by the Gq/11-type G-protein 
(Fathi et al., 1998; Wang et al., 1998).  However, GalR2 has also been shown to couple to 
Gi/o and G12/13-type G-proteins in different immortalized cell lines (Lang et al., 2007).  It 
is thus possible that activation of GalR2 receptors could result in cellular excitation or 
inhibition depending on which G-protein it is coupled to. 
 Previous attempts to generate systemically active, receptor-selective, galanin 
agonists have produced two compounds: galmic and galnon (Saar et al., 2002; Bartfai et 
al., 2004).  However, both compounds were shown to interact with non-galanin receptors 
in the micromolar (µM) range, thereby limiting their use as pharmacological tools (Lu et 
al., 2005a).  To address this issue, Bulaj and colleagues have successfully designed a 
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series of truncated galanin analogs in which nonessential amino acid residues are 
replaced by cationic and/or lipoamino acid residues (Bulaj et al., 2008).  One analog from 
this group, NAX-5055, was demonstrated to possess a 15-fold preference for GalR1 over 
GalR2 with nanomolar (nM) affinity (Bulaj et al., 2008; White et al., 2009).  NAX-5055 
was found to be effective against 6 Hz psychomotor seizures; thus demonstrating that a 
GalR1-preferring galanin agonist can exert an antiseizure effect (Bulaj et al., 2008).  
 In this study, we hypothesized that the GalR1-preferring galanin analog NAX-
5055 would reduce hippocampal excitability by modulating glutamatergic synaptic 
transmission.  Furthermore, we hypothesized that this modulation would result from a 
presynaptic mechanism of action, consistent with the lowering of frequency facilitation 
observed in the presence of overexpressed galanin.  To directly test this hypothesis, we 
recorded miniature excitatory postsynaptic currents (mEPSCs) from CA3 pyramidal 
neurons in the presence of NAX-5055 in mouse organotypic hippocampal slice cultures 
(OHSC).  Analysis of the inter-event interval and amplitude of mEPSC events in CA3 








 Timed pregnant female C57BL/6J mice arrived in our animal facility at 
embryonic day 16 (Charles River, Kingston, WA).  Mouse pups were born between 4-5 
days after arrival.  Animals were housed in a temperature-, humidity-, and light-
controlled (12 h light:dark cycle) facility.  Two dams were housed per cage and provided 
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free access to food (LabDiet) and water. All experimental procedures were performed in 
accordance with the guidelines established by the National Institutes of Health and 
received approval from the University of Utah’s Animal Care and Use Committee.  Dams 




Hippocampal Slice Preparation 
 Slice cultures were prepared using a modification of the the method originally 
described by Stoppini et al. (1991) (Alex et al., 2011).  On postnatal day 5 (P5), 
C57BL/6J mouse pups were anesthetized with pentobarbital (25 mg/mL) and rapidly 
decapitated.  Brains were extracted and the cerebellum was removed.  Hemispheres were 
cut into 350 µm transverse sections using a McIlwain tissue chopper (Stoelting Co., 
Wood Dale, IL) and placed in chilled Gey’s Balanced Salt Solution (GBSS, Sigma-
Aldrich, St. Louis, MO) supplemented with 6.5 mg/mL glucose.  Sections were separated 
under a dissection microscope and excess cortex removed to obtain intact hippocampal 
slices with the entorhinal cortex attached.  Hippocampal sections were transferred to 
tissue culture membrane inserts (Millipore) in a 6-well tissue culture dish containing 
medium consisting of 50% minimum essential medium with Glutamax and HEPES, 25% 
Hanks balanced salt solution, 25% heat inactivated horse serum (all from Sigma-Aldrich, 
St. Louis, MO), and 6.5 mg/mL glucose.  Medium was changed three times per week.  
Cultures were maintained at 37°C with 5% CO2 balanced humidified air in a standard 







 On the day of recording, a membrane insert with 3-4 hippocampal cultures was 
removed from the 6-well culture plate and placed in a sterile petri dish that contained 
external recording solution containing (in mM): 150 NaCl, 3 KCl, 2 CaCl2, 1.3 MgCl2, 10 
HEPES, 10 glucose at pH 7.30 and osmolarity of 305 mOsm.  External solution was 
stored in the incubator at 37°C.  Slices were removed from petri dishes by cutting a 
portion of the membrane insert surrounding a single slice with a sterile scalpel and 
immediately placed into a perfusion recording chamber.  The remaining slices on each 
insert were returned to the incubator for later use.  Once in the recording chamber, slices 
were submerged and perfused at 2 mL/min with external recording solution.  All 
recordings were performed at room temperature.  To isolate miniature excitatory 
postsynaptic currents (mEPSCs), tetrodotoxin (TTX, 1 µM) and picrotoxin (PTX, 50 µM) 
were added to the external recording solution immediately before use.  Whole cell 
recording pipettes (3-5 M#) were pulled on a PIP5 pipette puller (HEKA Instruments 
Inc., Bellmore, NY) and filled with internal recording solution containing (in mM): 140 
CsMeSO4, 20 HEPES, 5 EGTA (CsOH), 0.5 CaCl2, 10 Glucose, 2 Na2ATP, 0.5 NaGTP, 
5 TEA-Cl at pH 7.30 and osmolarity of 300 mOsm.  Biocytin (2 mg/mL) was added to 
intracellular recording solutions immediately before use to allow for visualization of the 
location and morphology of patch-clamped neurons.   
Whole cell recordings were obtained using the visualized patch technique.  The 
pyramidal cell layer of CA3 was visualized with a 40x water immersion objective (NA 
0.8, Carl Zeiss, Thornwood, NY) using infrared differential interference contrast (IR-
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DIC) microscopy on an upright Axioskop2 microscope (Carl Zeiss, Thornwood, NY).  
Voltage-clamp recordings were obtained in the whole-cell patch configuration using an 
Axopatch 200B amplifier and the CLAMPEX software package interfaced to a Digidata 
1322A data acquisition board (Axon Instruments, Union City, CA).  Recordings were 
acquired at 10 kHz for offline analysis using Clampfit 9 and Mini Analysis.  Neurons 
were voltage clamped to -70 mV for the duration of the experiment.  Membrane (Rm) and 
access (Ra) resistance were measured by using a 5-mV voltage step at the end of every 
30-second sweep for the duration of the recording.  Fluctuations greater then 20% of 
baseline holding current, Rm, or Ra across the duration of the experiment resulted in cells 
being excluded from further analysis.  Only one cell was recorded per slice.  The results 
from a total of 6 cells were included in this study. 
 After obtaining a gigaohm seal and entering the whole-cell configuration, 
voltage-clamped neurons were allowed to stabilize for approximately 10 min.  Based on 
the stability of the holding current, Ra, and Rm, experiments with NAX-5055 were 
initiated or cells were abandoned.  mEPSCs were recorded continuously for 35 min; 10 
min of baseline in the presence of TTX and PTX, followed by a 15 min perfusion of 
NAX-5055, followed by a10 min drug washout period.   
 
 
Immunohistochemistry and Imaging 
At the conclusion of the recording protocol, slice cultures were immediately 
transferred to culture wells containing 4% paraformaldehyde in 1x phosphate buffered 
saline (PBS) for 24 hr at 4°C for fixation, and subsequently stored in 1x PBS until 
staining.  For slice processing, slices were rinsed twice in 1x PBS and blocked with 4.5% 
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normal goat serum in 0.3% PBT (1x PBS + 0.3% Triton-X 100) for 4 hr.  Slices were 
then incubated overnight with streptavidin conjugated to Cy3 (1:500) and NeuN 
conjugated to Alexa 488 (1:500) in 0.1% PBT and 4.5% normal goat serum at room 
temperature.  On the following day, slices were rinsed in 1x PBS containing 4$,-6-
diamidino-2-phenylindole (DAPI, 0.1 µg/mL, Santa Cruz Biotechnology, Santa Cruz, 
CA) for 30 min, followed by the final wash steps in 1x PBS.  Slices were then mounted 
and coverslipped in Prolong gold anti-fade reagent (Invitrogen, Carlsbad, CA). 
Slides were imaged to confirm cell morphology and location under epifluoresence 
conditions using an upright Axio Imager.A1 microscope (Carl Zeiss, Thornwood, NY) 




 All mEPSCs were detected and analyzed using Mini Analysis software 
(Synaptosoft, Fort Lee, NJ).  Prior to detection traces were subject to a low-pass Elliptic 
filter at 700 Hz.  The detection threshold for mEPSCs was set to 10 pA, to limit inclusion 
of false positive events. 
 In order to normalize raw data, a percent control value was calculated for inter-
event interval and amplitude of mEPSCs, as well as holding current, Rm, and Ra.  Percent 
control was calculated by taking an average of the values recorded during the final 2 
minutes of baseline.  Each raw value was then divided by the generated average and 
multiplied by 100 resulting in an individual percent control value.  Time course data is 
presented as mean ± standard error of the mean (SEM). 
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 To quantify differences in inter-event interval and amplitude of mEPSCs, 
recorded values during the final 5 minutes of each recording period (baseline, NAX-
5055, and washout) for each cell were used and are presented as mean ± SEM.  A paired 
t-test was used to determine significance between recording periods.  Significance was 
set at p < 0.05.  Analysis was completed with Microsoft EXCEL and GraphPad Prism 






Mouse Organotypic Hippocampal Slice Cultures 
 To determine if our culture methods would alter the characteristic structural 
lamination of the hippocampus, we stained mouse organotypic hippocampal slice cultures 
(OHSC) with the neuronal marker NeuN after at least 7 days in vitro (DIV).  Staining 
patterns demonstrate that the classic lamination of pyramidal cell layers is maintained in 
our slice cultures, with the dentate gyrus and both CA1 and CA3 clearly visible and 
easily distinguished (Figure 2.1A).  All recorded cells were filled with biocytin during 
recording and then fixed and processed for immunofluorescence to determine cell type 
and confirm location.  Figure 2.1B illustrates a biocytin-filled pyramidal neuron within 
the CA3 region of the OHSC that co-localizes with the neuronal marker NeuN.  On 
occasion, astrocytes were patch clamped and were excluded from further analysis. 
 
 
Inter-event Interval and Amplitude of mEPSCs 
 
 It has been suggested that the anticonvulsant properties of the neuropeptide 





Figure 2.1. Images of a typical organotypic hippocampal slice in culture and biocytin-
filled CA3 pyramidal neuron.   
 
A) NeuN stain of a typical 7 DIV mouse organotypic hippocampal slice culture that was 
used in recordings.  Hippocampi retain their laminar structure with the dentate gyrus 
(DG) and pyramidal cell layers CA3 & CA1 remain intact.  Slices were cultured with the 
entorhinal cortex (EC) attached. 
 
B) Staining for biocytin following whole-cell recordings.  Biocytin (red) perfuses 
throughout recorded CA3 pyramidal neuron allowing for visualization of neuronal 
morphology and location within the slice.  Neuronal identity is confirmed by co-labeling 









Figure 2.2. NAX-5055 increased the mEPSC inter-event interval in mouse OHSC. 
 
A) Recording in the presence of TTX (1 µM) and PTX (50 µM) blocked all action 
potential- and GABA-mediated events allowing for resolution of the mEPSCs.  These 
events were considered the baseline for each cell recorded (n = 6 cells) 
 
B) Representative traces of mEPSCs recorded during the 15-min perfusion of NAX-5055 
(500 nM).   
 
C) Inter-event interval expressed as percent control begins to increase following 
perfusion of NAX-5055 (blue) and continues to increase for the duration of the 15-min 
exposure.  Values do not return to baseline during a 10-min washout period. 
 
D) The amplitude of mEPSCs expressed as percent control remains relatively stable for 
the duration of the recordings.   
 
E) There is a significant increase in the inter-event interval during the last five minutes of 
recording in the presence of NAX-5055 (paired t-test, p < 0.05).   
 
F) There is no significant difference in the amplitude of mEPSCs during the last five 



















































































(Zini et al., 1993; Mazarati et al., 2000).  To elucidate whether the anticonvulsant 
efficacy of the GalR1-preferring analog NAX-5055 exhibits a similar mechanism of 
action, we measured the effect of NAX-5055 on mEPSCs in CA3 pyramidal neurons.  
Figures 2.2A and 2.2B show representative traces of recorded mEPSCs under baseline 
conditions and after NAX-5055 (500 nM) exposure, respectively.  NAX-5055 (500 nM) 
produced a gradual increase in the inter-event interval across the duration of the 15 min 
drug-wash period.  However, the 10 min washout period was insufficient to reverse this 
effect (Figure 2.2C).  There was little variability in the amplitude of mEPSCs throughout 
the duration of the recordings (Figure 2.2D).  Quantification of the last 5 min of each 
recording period (baseline, NAX-5055, and washout) demonstrated a significant increase 
in the inter-event interval in the presence of NAX-5055 when compared to baseline levels  
(Figure 2.2E, p < 0.05, n = 6 cells).  In contrast, there was no change in amplitude of 
mEPSCs (Figure 2.2F, p > 0.05, n = 6 cells).  There was no significant difference 
between NAX-5055 and the washout period for either inter-event interval or amplitude 




 In this study we have shown that the GalR1-preferring galanin analog, NAX-5055 
increases the inter-event interval of mEPSCs without affecting the amplitude of these 
events in CA3 pyramidal neurons in mouse OHSC.  Together, these data suggest that the 
site of activity for NAX-5055 is largely presynaptic.  To our knowledge, this is the first 
demonstration of a synthetic galanin analog found to affect the probability of presynaptic 
glutamate release within the hippocampal formation.  Further, these observations suggest 
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that one mechanism of action for the anticonvulsant activity of NAX-5055 is the 
reduction of neuronal excitability via inhibition of presynaptic glutamate release onto 
CA3 pyramidal neurons. 
 It has been well documented that organotypic slice cultures retain the anatomical 
and physiological properties that are observed in more classically used acute 
hippocampal brain slices. (Zimmer and Gähwiler, 1984; 1987; Gähwiler et al., 1997).  
Thus, it seems unlikely that differences in the expression and localization of galanin 
receptors in the OHSC account for the affects we have observed in the present study.  In 
fact, preliminary evidence in our lab has suggested that NAX-5055 also increases inter-
event interval of mEPSCs without affecting amplitude in CA3 pyramidal neurons in acute 
hippocampal brain slices from C57BL/6J mice.  These data are consistent with what we 
have reported here using mouse OHSC.   
 Utilization of mouse OHSC allows for future study of the physiological effects 
associated with repeated agonist exposure of galanin receptors expressed on pyramidal 
neurons.  This is particularly interesting given that both the GalR1 and GalR2 receptors 
have been shown to internalize following agonist exposure in immortalized cell lines 
expressing either receptor type (Wang et al., 1998; Xia et al., 2005; 2008).  Once 
internalized, GalR1 receptors are known to be trafficked to lysosomes and degraded (Xia 
et al., 2008).  However, the regulation and trafficking patterns of galanin receptors have 
yet to be verified in neurons.  In addition, repeated systemic administration of NAX-5055 
results in a rapid decrease in anticonvulsant efficacy and the mechanism of this response 
remains unclear (see Chapter 3).  Characterization of the physiological activity of NAX-
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5055 in mouse OHSC will allow us to further address how galanin receptors are regulated 
in functional neurons. 
 The observed reduction of glutamate release in the hippocampus by NAX-5055 is 
consistent with previous work demonstrating that exogenously applied or overexpressed 
galanin can reduce glutamate release in acute hippocampal slices (Zini et al., 1993; 
Mazarati et al., 2000).  Short-term plasticity studies of the mossy fiber-CA3 synapse have 
been utilized to assess the potential presynaptic mechanism for the galanin-induced 
reduction in glutamate release (Zucker and Regehr, 2002).  Under basal conditions the 
mossy fiber-CA3 synapse displays short-term plasticity in the form of paired-pulse 
facilitation (PPF) and frequency facilitation; an action likely due to a low probability of 
vesicular release (Cremer et al., 1998; Lawrence et al., 2004; Nicoll and Schmitz, 2005).  
In transverse hippocampal slices from mice overexpressing galanin via the platelet 
derived growth factor B promoter, frequency facilitation of fEPSPs at the mossy fiber-
CA3 synapse is lowered, suggesting galanin can act presynaptically (Kokaia et al., 2001).  
However, no change in PPF or frequency facilitation of fEPSPs is observed in dorsal 
hippocampal slices when galanin is overexpressed using a recombinant adeno-associated 
viral vector (Kanter-Schlifke et al., 2007).  This lack of effect may result from the low 
expression of galanin receptor mRNA in the dorsal hippocampus (Burgevin et al., 1995).  
Although changes in short-term plasticity suggest a presynpatic mechanism for galanin, 
analysis of mEPSCs can not distinguish an increase or decrease in presynaptic glutamate 
release.  Our data supports the hypothesis that galanin limits hippocampal excitability 
through presynaptic mechanisms and also expands this hypothesis by suggesting that 
galanin could interact with GalR1 receptors to reduce presynaptic glutamate release onto 
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CA3 pyramidal neurons.  Further study is required in order to demonstrate that it is 
indeed the GalR1 receptor that mediates the inhibitory effect in NAX-5055 in CA3. 
 In the dentate gyrus, galanin and the nonpeptide agonist galmic inhibit PPF of 
fEPSPs following a 500-1000 ms inter-stimulus interval (Badie-Mahdavi et al., 2005a; 
2005b).  The long inter-stimulus intervals appear critical for this effect, as no effect of 
galanin on PPF was observed in other studies utilizing shorter inter-stimulus intervals 
(Mazarati et al., 2000; Kinney et al., 2009).  Isolation of the GalR2 receptor using the 
galanin fragment Gal(2-11) produced no effect on PPF at any inter-stimulus interval 
(Badie-Mahdavi et al., 2005b).  In the GalR1 knockout mouse, neither galanin nor Gal(2-
11) had any effect on PPF, suggesting that the delayed reduction in PPF seen with galanin 
and galmic is GalR1 dependent (Badie-Mahdavi et al., 2005b).  Thus, similar to what we 
report in CA3, galanin may modulate presynaptic release through a GalR1-dependent 
mechanism within the dentate gyrus.  Additional studies with NAX-5055 in the dentate 
gyrus and other regions of the hippocampus will further clarify the role of GalR1 in 
modulating hippocampal excitability. 
 Although our work has focused on the anti-seizure effects of NAX-5055, galanin 
has been also been well documented to negatively impact cognition.  Indeed, central 
administration or overexpression of galanin impairs performance in a number of learning 
and memory tasks (Crawley, 2008).  Consistent with these behavioral effects, galanin and 
Gal(2-11) have been shown to attenuate long term potentiation (LTP) in both the dentate 
gyrus and CA1 induced by either high frequency stimulation or theta-burst stimulation 
(Coumis and Davies, 2002; Badie-Mahdavi et al., 2005b; Kinney et al., 2009).  It has 
been suggested that the inhibitory effects of galanin working through the GalR2 receptor 
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on LTP are postsynaptic, based on the inability of Gal(2-11) to inhibit PPF (Badie-
Mahdavi et al., 2005b).  However, it remains unclear what role the GalR1 receptor plays 
in the modulatory affects of galanin on LTP.  The results of the studies reported here 
suggest that GalR1 receptors could modulate neuronal excitability through a presynaptic 
mechanism.  It is interesting to speculate that galanin may affect LTP through both pre- 
and post-synaptic mechanisms, mediated by the two different receptor subtypes.  Studies 
utilizing the receptor preferring agonists NAX-5055 and Gal(2-11) will allow for more 
rigorous testing of this hypothesis. 
 Although NAX-5055 provides us a novel tool to study galanin receptors, it is 
curious that the inter-event interval of mEPSCs dose not return to pre-NAX-5055 levels 
following the washout period.  In these studies, a 10 min washout period was always 
used, however in preliminary studies washout periods of up to 40 min were insufficient 
for inter-event interval values to return to baseline.  The inability to washout the effects if 
NAX-5055 could result from activating G-protein coupled receptor signaling cascades, 
which can modulate cellular activity for minutes to hours after agonist washout.  In 
addition, the lack of washout may result from the chemical modifications that were added 
to NAX-5055 to increase its metabolic stability in vivo.  In particular, the addition of a 
lysine-palmitoyl tail that increases the lipophilicity of NAX-5055 (Bulaj et al., 2008), 
may make the peptide difficult to completely washout of the slice preparation.  As a 
result it may be difficult to completely remove NAX-5055 once it has been added to the 
slice.  Additional studies using the scrambled NAX-5055 isomer 805-1, which lacks 
binding affinity for galanin receptors will help address this issue. 
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 In conclusion we have shown that NAX-5055 reduces presynaptic glutamate 
release onto CA3 pyramidal neurons.  This action may serve as one mechanism to 
explain the anti-seizure activity of this peptide.  To our knowledge, this is the first 
demonstration of a GalR1-preferring galanin analog directly affecting the probability of 
glutamate release in the hippocampus.  These observations provide the groundwork to 
further study the role of the GalR1 receptor in the regulation of neuronal excitability 
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DIFFERENTIAL ANTISEIZURE EFFECTS OF THE GALR1 PREFERRING 
AGONIST NAX-5055 FOLLOWING ACUTE AND 
 REPEATED ADMINISTRATION 
 
Abstract 
 The neuropeptide galanin is widely expressed in the central nervous system and 
plays an important role in inhibiting seizure activity.  There are three cloned galanin G-
protein coupled receptors (GalR1-3).  GalR1 and GalR2 receptors are expressed in brain 
regions prone to hyperexcitability.  The role of each receptor subtype in the inhibition of 
seizure activity remains unclear.  To address this issue we have developed the GalR1-
preferring galanin analog NAX-5055 that displays potent anti-seizure activity in a variety 
of epilepsy and seizure models.  The goal of the present study was to acess the disease-
modifying potential of NAX-5055 in the corneal kindled mouse model of partial 
epilepsy.  When administered by intraperitoneal (i.p.) injection one hour prior to each 
kindling stimulation, NAX-5055 did not exert any effect on the rate of kindling 
acquisition.  We next evaluated the antiseizure efficacy of NAX-5055 following acute or 
repeated dosing in the mouse 6 Hz seizure test, a model of partial seizure.  A single acute 
dose of NAX-5055 was effective in the 6 Hz test.  In contrast, the efficacy of NAX-5055 
was markedly reduced when it was administered i.p. once daily for three consecutive 
days prior to the 6 Hz challenge.  As a result, the focus of this study shifted to 
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understanding potential mechanism(s) that could underlie the reduced efficacy of NAX-
5055 following repeated administration.  To test the role of central galanin receptors, 
dose response studies were conducted.  We compared mice treated with an acute dose or 
repeated (once daily (i.p.) for three consecutive days followed by a final challenge) doses 
of NAX-5055.  The acute or final dose of NAX-5055 was administered i.p. or 
intracerebroventricular (i.c.v.) prior to the 6 Hz test.  A significant rightward shift of the 
dose response curve was noted in the group that received repeated i.p. doses of NAX-
5055.  In contrast, when the last dose of NAX-5055 was administered i.c.v., no 
significant difference in the dose-response curves between groups was observed.  These 
results suggest that central galanin receptors can mediate anti-seizure activity if NAX-
5055 can gain access to them.  In a subsequent study designed to evaluate the role of 
efflux transport, it was found that NAX-5055 does not serve as a substrate for the efflux 
transporter p-glycoprotein (P-gp).  These results suggest that the reduction in anti-seizure 
activity following repeated NAX-5055 administration is not dependent on modified 
central galanin receptor availability or increased efflux transport by P-gp.  However, the 
reduction in potency of following repeated NAX-5055 adminstration may explain the 
failure of NAX-5055 to affect kindling acquisition rate.  Additional investigations are 





 It is estimated that there are 50 million epilepsy patients worldwide, with nearly 
150,000 new cases diagnosed annually in the United States alone (Hirtz et al., 2007; 
Institute of Medicine, 2012).  Approximately 30% of epilepsy patients are considered 
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drug-resistant.  These patients display inadequate seizure control following treatment 
with at least two different antiepileptic drugs in either mono- or poly-therapy (Kwan and 
Brodie, 2003; Cascino, 2008; Kwan et al., 2010a).  Neuropeptides, including galanin and 
neuropeptide Y, display increased expression following experimentally induced seizures 
(Wilson et al., 2005).  In addition, neuropeptides display antiseizure activity in a variety 
of epilepsy animal models (Baraban, 2004; Lang et al., 2007).  Thus, neuropeptides and 
their cognate receptors provide novel, pathologically relevant, targets for therapeutic 
development (Robertson et al., 2011; Weinberg and McCown, 2011).   
 Galanin is a 29-amino acid (30 in humans) endogenous neuropeptide expressed 
throughout the central nervous system; including limbic brain structures known to be 
involved in ictogenesis (Lang et al., 2007; Lerner et al., 2008).  Within the hippocampus, 
galanin is expressed in cholinergic projections from the medial septum and noradrenergic 
projections originating from the locus coeruleus (Consolo et al., 1994; Mazarati et al., 
1998; Xu et al., 1998).  In animal models of status epilepticus, galanin immunoreactivity 
within these projections is markedly reduced, likely due to increased release and 
exhaustion of galanin stores (Mazarati et al., 1998; Lerner et al., 2008).  However, de 
novo neuronal immunoreactivity in the hilar region and increased mRNA expression of 
galanin throughout the hippocampus is also observed following status epilepticus 
(Mazarati et al., 1998; Wilson et al., 2005).  These observations suggest endogenous 
galanin levels display robust plasticity in response to seizure activity. 
 Investigation of the antiseizure properties of galanin has relied heavily on 
experimentally enhancing central galanin expression levels.  Direct galanin injection into 
the hilus or overexpression using transgenic mice leads to increased resistance to the 
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induction of status epilepticus and reduced pentylenetetrazol-induced seizure severity 
(Mazarati et al., 1992; 1998; 2000).  Overexpression of galanin also increases after-
discharge threshold in kindled mice and delays the rate of kindling acquisition (Kokaia et 
al., 2001; Kanter-Schlifke et al., 2007).  One potential mechanism for the anti-seizure 
activity of galanin is inhibition of stimulated glutamate release within the hippocampus 
(Zini et al., 1993; Mazarati et al., 1998).  Together these studies suggest that galanin, at 
experimentally increased concentrations, can effectively modulate neuronal excitability 
and seizure activity. 
 There are three known galanin receptors (GalR1, 2, and 3) belonging to the G-
protein coupled receptor family (Habert-Ortoli et al., 1994; Parker et al., 1995; Smith et 
al., 1997).  All three galanin receptors are expressed at varying levels throughout the 
brain (for review see (Branchek et al., 2000)).  [125I] galanin binding and in situ 
hybridization studies are consistent in the demonstration of moderate to high expression 
patterns for both GalR1 and GalR2 receptors within the ventral hippocampus (Burgevin 
et al., 1995). High levels of GalR2 receptor expression are also observed in the dentate 
gyrus (O'Donnell et al., 1999).  GalR3 receptors are expressed at low levels in the brain, 
with expression in discrete regions including hypothalamus and pituitary (Smith et al., 
1997).  However, the lack of specific galanin receptor antibodies has made it difficult to 
confirm region and cell-type specific protein levels within the brain (Lu and Bartfai, 
2009). 
 Similar to many neuropeptide receptors, the GalR1 receptor selectively couples to 
the Gi-type G-protein (Branchek et al., 2000).  Receptor activation inhibits forskolin-
stimulated cAMP production (Habert-Ortoli et al., 1994), opens G-protein regulated 
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inwardly rectifying K+ (GIRK) channels (Smith et al., 1998), inhibits voltage dependent 
Ca2+ influx (Endoh et al., 2008; Anselmi et al., 2009), and stimulates mitogen-activated 
protein kinase activity (Wang et al., 1998b).  The selective coupling of GalR1 to an 
inhibitory G-protein with downstream effects that can induce cell hyperpolarization make 
this receptor an interesting target for antiseizure drug development. 
 In contrast, the GalR2 receptor displays a more complicated signaling cascade 
capable of interacting with numerous G-proteins.  The most commonly observed pathway 
involves a Gq/11-type G-protein mediated activation of phospholipase C (PLC) resulting 
in release of Ca2+ from intracellular stores and opening Ca2+-dependent chloride channels 
(Fathi et al., 1998; Wang et al., 1998a).  Interestingly, GalR2 has also been shown to 
couple to Gi/o and G12/13-type G-proteins in immortalized cell lines (Lang et al., 2007).  It 
is thus possible that activation of GalR2 receptors could result in neuronal excitation or 
inhibition depending on specific G-protein coupling at the time of receptor activation.   
 It is currently unclear what role each galanin receptor subtype plays in mediating 
the anti-seizure properties of galanin.  Studies investigating transgenic mice have 
demonstrated that knock-out of the GalR1 receptor or knockdown of the GalR2 receptor 
increases seizure severity and cellular damage in status epilepticus animal models 
(Mazarati et al., 2004a; 2004b; Schauwecker, 2010).  In addition, spontaneous seizures 
have been observed in the GalR1 knockout mouse, further implicating this receptor in the 
regulation of neuronal excitability (McColl et al., 2006).  Despite these advances, there is 
still a lack of receptor-selective, systemically available agonists to aid in evaluating the 
role of each receptor subtype in mediating the antiseizure activity of galanin. 
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 Previous attempts to generate systemically active galanin agonists produced two 
compounds: galmic and galnon (Saar et al., 2002; Bartfai et al., 2004).  However, both 
compounds were found to interact with non-galanin receptors in the micromolar (µM) 
range; thereby limiting their use as pharmacological tools (Lu et al., 2005).  To address 
this issue Bulaj and colleagues successfully designed a series of truncated galanin analogs 
in which nonessential amino acid residues were replaced by cationic and/or lipoamino 
acid residues (Bulaj et al., 2008).  One analog from this group, NAX-5055, displays 
nanomolar affinity for both galanin receptors and a 15-fold preference for GalR1 over 
GalR2 (Bulaj et al., 2008; White et al., 2009).  Furthermore, NAX-5055 possesses a 
broad-spectrum anti-seizure profile in a variety of animal seizure and epilepsy models 
following systemic administration.  This profile provides important proof of concept that 
a GalR1-preferring galanin agonist can inhibit seizure activity in vivo (Bulaj et al., 2008).  
 In this study we sought to further characterize the anti-seizure activity of NAX-
5055.  Previous studies have demonstrated that kindling acquisition is delayed in mice 
and rats overexpressing galanin in the brain (Kokaia et al., 2001; Kanter-Schlifke et al., 
2007).  In this study we evaluated the potential of NAX-5055 to modulate the rate of 
kindling acquisition in the corneal kindled mouse model of partial epilepsy.  Given early 
results in the 6 Hz seizure model suggesting that the efficacy of NAX-5055 was reduced 
with repeated administration, we became interested in the mechanism(s) underlying this 
effect.  NAX-5055 preferentially interacts with GalR1 receptors, which have been shown 
to be internalized and degraded following acute agonist exposure in immortalized cell 
lines (Wang et al., 1998a; Xia et al., 2008).  Thus, we evaluated the effects of repeated 
activation of galanin receptors on the anti-seizure potency of NAX-5055 in an effort to 
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establish whether receptor availability contributes to the observed decrease in efficacy.  
This study offers the first report describing the effects of repeated treatment with a 








 Adult male CF-1 mice weighing at least 18g (Charles River, Kingston, WA) 
where used for all experiments described in this study.  Animals were housed in a 
temperature-, humidity-, and light-controlled (12h light:dark cycle) facility.  Mice were 
group housed and allowed access to food and water ad libitum.  At the conclusion of all 
experiments animals were sacrificed immediately by CO2 asphyxiation.  All experimental 
procedures were performed in accordance with the guidelines established by the National 




Seizure and Epilepsy Models 
Corneal Kindling Acquisition 
 CF-1 mice were kindled according to the methods originally defined by Matagne 
and Klitgaard (Matagne and Klitgaard, 1998).  Briefly, mice were stimulated twice daily 
with a sub-convulsive corneal stimulation of 3 mA (60 Hz) for a 3-second duration.  
Daily stimulations were delivered with at least 4 hrs between stimulations.  Prior to each 
stimulation, a drop of 0.9% saline containing 0.5% tetracaine hydrochloride (Sigma-
Aldrich, St. Louis, MO) was applied to the cornea to ensure local anesthesia and good 
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electrical conductivity.  The evoked behavioral seizures were classified according to the 
five-stage Racine scale (Racine, 1972).  Stages 1 to 3 are considered partial seizures and 
stages 4 and 5 generalized seizures.  Mice not displaying any behavioral seizure activity 
were given a score of 0.  Mice were considered fully kindled after they had displayed five 
consecutive stage five seizures (see Figure 3.1).  Stimulations were continued until 
vehicle-treated mice reached a fully kindled state.  The corneal kindling model displays a 
behavioral phenotype and pharmacological profile that is consistent with human partial 
epilepsy (Rowley and White, 2010). 
 When testing NAX-5055 against fully kindled seizures mice were stimulated the 
day before testing to ensure the maintenance of the kindled state (n = 8 per treatment).  
To determine the effect of NAX-5055 on kindling acquisition, mice were administered 
NAX-5055 1 hr prior to each corneal stimulation for the duration of the kindling 
acquisition phase (i.e., two times daily) (NAX-5055-treated, n = 24; Vehicle-treated, n = 
16).  Kindling acquisition rate was determined by the number of stimulations required to 
reach each behavioral seizure stage and the fully kindled state. 
 
6 Hz psychomotor seizure test 
 Partial psychomotor seizures were evoked using an acute corneal stimulation (6 
Hz, 0.2 msec rectangular pulse width, 3-sec duration) with current generated by a Grass 
S48 stimulator (Grass Technologies, West Warwick, RI).  Current intensity was set to 32 
mA approximately 1.5 times the convulsive current necessary to generate a prototypical 
seizure in 97% of male CF-1 mice (Barton et al., 2001).  Prior to each stimulation, a drop 
of 0.9% saline containing 0.5% tetracaine hydrochloride (Sigma-Aldrich, St. Louis, MO) 
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was applied to the cornea to ensure local anesthesia and good electrical conductivity.  
Behavioral seizures were characterized by rhythmic twitching of the vibrissae, head 
nodding, forelimb clonus, and/or rearing and falling (Barton et al., 2001).  Mice not 
observed to display any of the above phenotypic features were scored as protected (i.e., 
100% protection). 
 
Peptide Design and Preparation 
 The galanin analog NAX-5055 was originally designed and synthesized at the 
University of Utah as previously described (Bulaj et al., 2008).  NAX-5055 was later 
synthesized in bulk by NeoMPS (San Diego, CA).  The inactive scrambled analog of 
NAX-5055, i.e. 805-1, in which Tyr2 and Trp9 were swapped, was also designed and 
synthesized at the University of Utah.  Solutions were prepared by dissolving synthesized 
peptides in 0.9% saline containing 1% Tween 20 (Sigma-Aldrich, St. Louis, MO).  
Solutions were made fresh daily.  Prior to each experiment the peptide concentration of 
each solution was confirmed by UV absorbance of tyrosine and tryptophan residues 
(Cary 50 Bio UV Spectrophotometer, Varian). 
 
 
Experimental Design and Dosing Regimen 
 Mice were removed from the colony, weighed, treated, tested, and either returned 
to the colony (in their home cage) or sacrificed between the hours of 8:00 AM and 5:00 
PM.  In all studies mice were randomly selected from their home cage and placed into 
experimental groups with no intentional bias.  Compounds were administered 
intraperitoneally (i.p.) in a volume of 0.01 mL/g body weight or intracerbroventricularly 
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(i.c.v.) in a volume of 5µL.  Whether mice received peptide or vehicle was dependent on 
the randomly assigned experimental group (see below).  Seizure responses in each 
behavioral model (i.e., corneal kindling or 6 Hz) were assessed at the time to peak effect 
of NAX-5055 based on the route of administration: 1 hr for i.p. injection and 15 min for 
i.c.v. injection.  All i.c.v. injections were done by free hand injection using a Hamilton 
microsyringe (Reno, NV) with a clear plastic guard to ensure proper needle depth. 
 
 
Acute and Repeated Administration of NAX-5055 (4 mg/kg) 
 
 In experiments that compared the effects of single or repeated doses of NAX-
5055, mice were split into one of three groups as depicted in Figure 3.2A (n = 8 per 
group).  Mice in Group 1 (vehicle) received vehicle for 4 days.  Mice in Group 2 (acute 
NAX-5055) received vehicle for the first 3 days and then a single injection of NAX-5055 
on the 4th day.  Mice in Group 3 (repeated NAX-5055) received NAX-5055 for all 4 
days.  Injections administered on days 1-3 were always given systemically (i.p.).  
Injections given on day 4 were administered either i.p. or i.c.v.  After the last injection on 
day 4, animals in all groups were subjected to the 6 Hz test at 32 mA. 
 
 
Repeated Administration of NAX-5055 and 805-1 
 
 In experiments designed to compare the effect of repeated doses of NAX-5055 
with 805-1, mice were split into one of four treatment groups as depicted in figure 3.3A 
(n = 8 per group).  Mice in Group 1 (vehicle) received vehicle for all 4 days.  Mice in 
Group 2 (acute NAX-5055) received vehicle for the first 3 days and a single injection of 
NAX-5055 on the 4th day.  Mice assigned to Group 3 (repeated NAX-5055) were treated 
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with NAX-5055 for all 4 days.  Mice in the final group; i.e., Group 4 (805-1) received 
805-1 for the first 3 days and then a single injection of NAX-5055 on the 4th day.  One 
hour after the last injection on day 4, animals in all groups were subjected to the 6 Hz test 
at 32 mA.  All treatments were administered i.p.. 
 
 
NAX-5055 Dose Response and ED50 Determination 
 
 For the dose response studies, mice were split into one of two groups.  Mice in the 
first group (acute NAX-5055) received vehicle for the first 3 days and then a single 
injection of NAX-5055 on the 4th day.  Mice in the second group (repeated NAX-5055) 
received NAX-5055 for all 4 days.  Injections administered on days 1-3 were always 
given systemically (i.p.).  Injections given on day 4 were administered either i.p. or i.c.v.  
After the last injection on day 4, animals in all groups were subjected to the 6 Hz test (32 
mA 1 hr after dosing).  Results from dose-response studies are expressed as the median 
effective dose (ED50) with corresponding 95% confidence intervals.  To generate these 
values, mice (in groups of at least n = 8) were tested at different doses of NAX-5055, 
until at least two points were established between the limits of 0% and 100% protection 
from seizure activity.  The number of mice tested at each dose and the percentage of 
those mice that displayed protection from seizure activity were entered into a log probit 
analysis program to generate ED50 and 95% confidence interval values.  Nonoverlapping 
confidence intervals were considered to demonstrate a significant shift in the dose-





Mouse p-glycoprotein Substrate ATPase Assay 
 To evaluate the potential interaction between NAX-5055 and the efflux 
transporter P-glycoprotein (P-gp), ATPase activity was measured using an in vitro 
colorimetric assay developed by BD Biosciences (Sarkadi et al., 1992; Drueckes et al., 
1995).  Substrate compounds for P-gp result in the cleavage of ATP to ADP and release 
of a free phosphate group that can be measured by using UV spectroscopy.  Membranes 
containing P-gp expressed from mouse mdr1a or mdr1b cDNA using a baculovirus 
expression system were obtained from Genetest (Woburn, MA).  Reactions were run on a 
96-well plate with 60-µL reaction mixtures.  Each well contained 40 µg membrane 
protein, NAX-5055, and 5 mM MgATP (20 µL of each) in a 50 mM Tris buffer 
containing 2 mM EGTA, 50 mM KCl, 2 mM dithiothreitol, and 5 mM sodium azide.  The 
concentration of NAX-5055 was varied between 3-300 nM.  Identical reactions were run 
in tandem with 100 µM sodium orthovanadate.  Orthovanadate inhibits P-gp by trapping 
MgATP in the nucleotide binding site.  This control increases the sensitivity of the assay 
by allowing for identification and subtraction of any non-specific ATPase activity.  
Verapamil, a known substrate for P-gp, was also run on all plates as a positive control.  
Reaction mixtures were incubated for 20 min at 37 °C. The reaction was stopped by the 
addition of 30 µl 10% SDS and Antifoam A.  An additional set of reactions were run in 
which MgATP was added post SDS.  The results from this reaction represent t = 0 min.  
Incubation was followed with the addition of 200 µl of the colorimetric reagent (35 mM 
ammonium molybdate in 15 mM zinc acetate combined with 10% ascorbic acid (pH 5.0) 
prepared each day (in a ratio of 1:4)).  The liberation of inorganic phosphate was detected 
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by its absorbance at 850 nm and quantified by comparing the absorbance of individual 




 Analysis of the corneal kindling acquisition rate was determined by averaging the 
number of stimulations required to reach each seizure stage during the acquisition 
process.  A two-way ANOVA was used to determine any difference in seizure scores 
observed between vehicle- and NAX-5055-treated groups. 
 For all experiments utilizing the 6 Hz psychomotor seizure test the non-
parametric Kruskal-Wallis test with a Dunn’s posttest analysis was used in order to 
compare treatment groups.  This statistical test was used due to the binary nature of 6 Hz 
test data (protected or unprotected).  Results of the ATPase assay were analyzed by 
fitting dose response data with the Michaelis-Menten model of simple enzyme kinetics to 
yield Vmax and Km values.  All differences between groups were considered to be 
significantly different when p < 0.05.  All statistical analysis described above was 






Acute Anti-seizure Profile of NAX-5055 
 
 The anti-seizure profile for the GalR1-preferring analog NAX-5055 was 
established previously using a battery of well-established animal seizure and epilepsy 
models.  The results of this investigation are summarized in Table 3.1 (White et al., 










Animal model                    ED50 (mg/kg)       Protective Indexa 
 
6 Hz psychomotor seizure (mouse) 
 22mA         0.7              30   
 32mA         0.8              26.3 
 44mA         2.9              7.2 
Fring’s Audiogenic (mouse)       3.2              6.5 
Corneal Kindled (mouse)       0.65        30 
Hippocampal Kindled (rat)       2.0              10.5 
Maximal Electroshock (mouse)      >20.0        <1 
s.c. PTZ (mouse)        25%  protection at 20.0          <1 
 
aTD50/ED50; TD50 = 21 mg/kg 
Adapted from White et al., 2009
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including the 6 Hz psychomotor seizure model (at 22, 32, and 44 mA current intensities), 
the corneal kindled mouse, and the hippocampal kindled rat. NAX-5055 is also active in 
the Frings audiogenic seizure model of reflex epilepsy. In contrast, NAX-5055 (up to 20 
mg/kg) displays little to no anticonvulsant activity in the maximal electroshock or s.c. 
PTZ models of generalized epilepsy.  NAX-5055 is well tolerated by animals with a TD50 




Effect of NAX-5055 on the Rate of Corneal Kindling Acquisition 
 The overexpression of galanin within the CNS has been demonstrated to delay 
kindling acquisition rate in both mice and rats (Kokaia et al., 2001; Kanter-Schlifke et al., 
2007).  NAX-5055 displays potent anti-seizure activity against fully developed rat 
hippocampal kindled seizures and mouse corneal kindled seizures (Table 3.1).  We 
hypothesized that NAX-5055, like galanin, would delay kindling acquisition.  To test this 
hypothesis, we evaluated the ability of NAX-5055 to modify kindling acquisition in the 
corneal kindled mouse model of partial epilepsy (Matagne and Klitgaard, 1998).  Of all 
the mice that received kindling stimulations, 87.5% (14/16) of vehicle-treated mice and 
70.8% (17/24) of NAX-5055-treated mice reached a fully kindled state, i.e. 5 consecutive 
stage 5 seizures within 32 stimulations.  Not all NAX-5055 treated mice became fully 
kindled (7/24); however, 91.7% (22/24) of mice treated with NAX-5055 displayed at 
least one generalized stage 5 seizure (Figure 3.1A).  Analysis of the number of 




Figure 3.1. NAX-5055 did not affect the rate of corneal kindling acquisition in mice. 
 
A.) Corneal kindling acquisition curves for vehicle- and NAX-5055-treated mice.  All 
mice were stimulated twice daily with a subconvulsive corneal stimulation of 3mA for 3 
sec.  NAX-5055 (4 mg/kg) or vehicle was administered 1 hr before corneal stimulation.  
Seizures were scored according to the 5-stage Racine scale.  Individual data points 
represent the average seizure score ± SEM following each stimulation. 
 
B) Average number of stimulations to reach each seizure stage and the fully kindled state; 
i.e., five consecutive stage 5 seizures.  No significant difference was seen between mice 
administered vehicle (n =16) or NAX-5055 (n = 24) (Two-way ANOVA, p > 0.05). 





























































Anti-seizure Efficacy of NAX-5055 is Reduced with Repeated  
Systemic Administration 
 One hypothesis to explain the failure of NAX-5055 to attenuate kindling 
acquisition is that the efficacy of NAX-5055 is reduced following repeated systemic 
administration.  To test this hypothesis, mice received an i.p. dose of NAX-5055 once  
daily for four consecutive days in the absence of any stimulation.  One hour following the 
4th and final injection of NAX-5055, mice were challenged in the 6 Hz psychomotor 
seizure test (Figure 3.2A).  Mice that received a single systemic dose of NAX-5055 (4 
mg/kg) displayed significant protection from the 6 Hz (32 mA) corneal stimulation 
(Figure 3.2B, n = 8 per group). In contrast, the anticonvulsant efficacy of NAX-5055 was 
markedly reduced in mice subjected to repeated systemic injections; e.g., only 25% of 
mice assigned to the repeated-dose group were protected in the 6 Hz test (Figure 3.2B, n 
= 8, per group). 
 The results shown in Figure 3.2B suggest that repeated systemic administration of 
NAX-5055 results in a robust decrease in antiseizure efficacy.  There are a number of 
possible mechanisms that could contribute to this phenomenon.  To begin to address this 
issue, we evaluated both pharmacodynamic and pharmacokinetic properties of NAX-
5055 in the mouse.  In this study we have focused on the role of the chemical 





Figure 3.2.  Repeated systemic administration of NAX-5055 reduces anti-seizure efficacy 
in the 6 Hz psychomotor seizure model. 
 
A) Schematic of the experimental design.  Mice were administered NAX-5055 (4 mg/kg, 
i.p.) or vehicle 1hr prior to a 6 Hz, 32mA corneal stimulation. 
 
B) NAX-5055 displays significant anti-seizure activity following acute administration 
(i.e., acute 5055).  In contrast, the anti-seizure efficacy of NAX-5055 is significantly 
reduced after four, once daily systemic injections (i.e., repeated 5055).  Mice were scored 
as either protected (100%) or unprotected (0%) in response to the 6 Hz corneal 
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 NAX-5055 was designed around the active galanin fragment Gal (1-13), which 
displays high affinity for the galanin receptors (Lang et al., 2007).  The chemical 
modifications made to this fragment were implemented to increase systemic availability 
(Bulaj et al., 2008; Robertson et al., 2011).  Studies with a scrambled peptide 805-1 
demonstrate that the galanin fragment is critical to the antiseizure activity of NAX-5055 
in the 6 Hz test (White et al., 2009).  The scrambled peptide 805-1 is identical to NAX-
5055 with the exception that Try2 and Trp9 are swapped.  These two residues are critical 
for the binding of galanin to its cognate receptors.  Indeed, 805-1 displays weak binding 
to galanin receptors in vitro (data not shown).  To determine if the active galanin 
fragment or chemical modifications were involved in the decreased efficacy of NAX-
5055 we tested whether repeated dosing with 805-1 would modify the antiseizure activity 
of NAX-5055 (Figure 3.3A).  As seen previously, a high percentage (75%) of mice were 
protected in the 6 Hz test with a single systemic 4 mg/kg dose of NAX-5055 (Figure 
3.3B).  In contrast, a low percentage (12.5%) of mice that received repeated doses of 
NAX-5055 (4 mg/kg, i.p.) were protected against the 6 Hz stimulation (Figure 3.3B).  
When mice were exposed to the scrambled peptide 805-1 once daily for three days and 
then treated with a single i.p. dose of NAX-5055 (4mg/kg) on the fourth and final day, 
100% of mice were protected in the 6 Hz test (Figure 3.3B, n = 8 per group).  The results 
of this study suggest that the integrity of the Gal(1-13) fragment of NAX-5055 is 





Figure 3.3. Repeated administration of the scrambled peptide 805-1 does not result in 
reduced efficacy of NAX-5055 in the 6 Hz psychomotor seizure model. 
 
A) Schematic of the experimental design. 
 
B) Bars represent the percentage of treated mice that were protected (i.e., showed no 
behavioral seizure activity) following a 6 Hz, 32 mA corneal stimulation.  NAX-5055 
and 805-1 were administered at 4 mg/kg, i.p.  Acute administration of NAX-5055 
displays significant anti-seizure activity (acute).  In contrast, mice exposed to repeated 
daily administration of NAX-5055 displayed a markedly attenuated anti-seizure response 
to NAX-5055 (repeated).  However, repeated daily administration of the scrambled 
peptide 805-1 did not negatively affect the efficacy of NAX-5055 (i.e., 3x 805-1 & NAX-
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Central Administration of NAX-5055 following Repeated Systemic  
Administration Restores Anti-seizure Efficacy 
 Galanin receptors have been demonstrated to internalize following agonist 
exposure in immortalized cell lines (Xia et al., 2005; 2008).  Once internalized the GalR1 
receptor, the preferred target of NAX-5055, is trafficked to lysosomes and degraded (Xia 
et al., 2008).  Thus, reduced efficacy to the systemic anti-seizure activity of NAX-5055 
could result from a reduction in galanin receptor availability within the brain.  To test this 
hypothesis, a group of 16 mice were administered NAX-5055 (4 mg/kg, i.p.) once daily 
for 3 days.  On the fourth day, mice were randomly split into two groups.  The first group 
received their fourth and final dose systemically (4 mg/kg, i.p.), whereas the second 
group received their final dose centrally (i.c.v.) (0.4 nmol/5µL).  The anti-seizure activity 
of NAX-5055 was evaluated using the 6 Hz test (32 mA).  Consistent with previous 
results (Figure 3.2B & 3.3B), mice that received repeated systemic injections of NAX-
5055 demonstrated minimal protection (12.5% protection) in the 6 Hz test (Figure 3.4A).  
In contrast, a high percentage (i.e., 75% protection) of mice that received their final dose 
of NAX-5055 via the i.c.v. route were considered protected in the 6 Hz test (Figure 
3.4B).  Mice that received a single i.c.v. injection of NAX-5055 demonstrated complete 
seizure protection (Figure 3.4B).  The demonstration that centrally administered NAX-
5055 restores the anti-seizure effect in otherwise resistant mice suggests that galanin 
receptors remain available for interaction with NAX-5055, assuming the agonist can gain 
access to the receptors. 
 To confirm that these observations were not specific to the 6 Hz psychomotor 
seizure test, similar experiments were conducted in corneal kindled mice (Figure 3.4C).  
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Figure 3.4. Central administration of NAX-5055 elicits anti-seizure activity in mice 
subjected to repeated systemic NAX-5055 administration. 
 
A) Mice were treated using the same dosing paradigm described in Figure 2A.  NAX-
5055 was administered at 4 mg/kg, i.p.  Bars represent the percentage of mice protected 
from seizures in the 6 Hz (32 mA) test.  Acute administration of NAX-5055 displays 
significant anti-seizure activity (grey bar).  In contrast, repeated daily administration of 
NAX-5055 significantly attenuates anti-seizure activity (black bar).  Kruskal-Wallis test, 
**p < 0.01, ***p < 0.001, n = 8 per group. 
 
B) Mice were treated using a similar dosing paradigm described in Figure 3.2A.  
However, the final injection of NAX-5055 (0.4 nmol/5µl) or vehicle was administered 
i.c.v.  Acute administration of NAX-5055 displays significant anti-seizure activity (grey 
bar).  When the final injection of NAX-5055 is administered i.c.v. in repeatedly treated 
mice, there is no attenuation of anti-seizure activity (black bar).  Kruskal-Wallis test, **p 
< 0.01, n = 8 per group 
 
C) Corneal kindled mice were administered NAX-5055 (4 mg/kg) once daily for seven 
days.  Initial NAX-5055 administration reduced the average seizure severity from a 
generalized stage 5 seizure to an average of a stage 2 seizure.  The reduction in seizure 
severity was attenuated with every additional NAX-5055 administration and subsequent 
stimulation.  However, partial anti-seizure activity was observed following i.c.v (0.4 
nmol/5µL) injection in mice resistant to the systemic effects of NAX-5055.  Mice given 
only vehicle injections displayed stable stage 5 seizure activity for the duration of the 
experiment (n = 8 per group). 
  































































Mice were fully kindled and confirmed to display consistent stage 5 seizure activity prior 
to initiating treatment with NAX-5055 (4 mg/kg) or vehicle i.p..  Control mice that 
received vehicle injections throughout the study displayed stable stage 5 seizures in 
response to daily stimulations.  Following the first injection of NAX-5055, 62.5% (5/8) 
of corneal kindled mice were protected and displayed no behavioral seizure activity 
(stage 0), while the remaining 37.5% (3/5) mice were not protected and displayed stage 5 
seizures (Figure 3.4C).  Following each additional injection of NAX-5055 and 
stimulation, the number of animals displaying protection from seizure activity decreased.  
By the 5th day of systemic NAX-5055 administration all mice had become resistant to the 
anti-seizure effects of NAX-5055 and displayed stage 5 seizures following stimulation.  
However, the subsequent i.c.v. injection of NAX-5055 (0.4 nmol/5µL) to this group 
partially recovered the anti-seizure activity of NAX-5055.  Fifty percent of the previously 
nonprotected mice displayed reduced seizure severity (stage 1-3 seizures), while the other 
50% remained resistant and displayed stage 4/5 seizures (Figure 3.4C, n = 8 per group).   
These results suggest that the reduced anti-seizure efficacy of NAX-5055 is not model 
specific and supports the conclusion that central galanin receptors are available to be 
engaged if the agonist can gain access to the receptors. 
 In order to confirm that previous results are not specific to a single dose of NAX-
5055, dose-response studies were conducted. To generate dose-response curves, mice 
were treated with a single acute dose or repeated (i.e., once daily for three consecutive 
days) doses of NAX-5055.  Similar to previous experiments, the final injection was 
administered either systemically (i.p.) or centrally (i.c.v.) and mice were then subjected to 
the 6 Hz test.  The dose of NAX-5055 was varied to obtain a dose response.  As shown in 
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Figure 3.5A, a marked shift to the right in the dose-response curve was noted in those 
mice that received repeated systemic doses of NAX-5055 for 3 days followed by a final 
systemic challenge dose of NAX-5055.  Despite the increase in dose needed to reach 
100% protection in the repeatedly treated mice (up to 20 mg/kg) no significant motor 
toxicity was observed (data not shown).  In contrast, no significant shift in the dose-
response curves was observed when the final NAX-5055 dose was administered i.c.v. 
(Figure 3.5B).  In this study, some mice displayed a loss of righting reflex at the highest 
i.c.v. dose tested (i.e. 4 nmol/5µL) and were excluded from analysis because their 
response to stimulation in the 6 Hz test could not be discerned.  The ED50 and 95% 
confidence intervals for both of these studies are summarized in Table 3.2. 
 
 
Transport of NAX-5055 
 Of the myriad of possible mechanisms that could account for the notable 
reduction in efficacy to NAX-5055 following repeated systemic administration, efflux 
transport out of the brain is a possible mechanism.  The ABC efflux transporter P-gp is 
well documented to remove xenobiotic compounds from the brain (Aronica et al., 2011).  
To evaluate whether P-gp could transport NAX-5055, we tested the substrate activity of 
NAX-5055 for the two isoforms of P-gp in mice, mdr1a and mdr1b.  To transport 
compounds across membranes, P-gp requires energy in the form of adenosine triposphate 
(ATP) (Sauna and Ambudkar, 2007).  Interaction of P-gp with a substrate compound 
results in the cleavage of ATP to ADP and the release of a free inorganic phosphate 
group, which can be measured using a colorimetric assay (Sarkadi et al., 1992).  




Figure 3.5. Dose response curves following acute and repeated NAX-5055 treatment. 
 
A) Dose response curves for mice administered acute or repeated systemic injections of 
NAX-5055.  Results are plotted as the percentage of mice protected from seizure activity 
in the 6 Hz (32mA) test.  The repeated-treatment, dose-response curve displays a 
significant rightward shift.  This suggests a decrease in potency of NAX-5055 following 
repeated administration (n = 8-16 per dose per group). 
 
B) Dose response curves for mice receiving NAX-5055 i.c.v.  Repeatedly dosed mice 
received three, once daily systemic NAX-5055 injections (4 mg/kg, i.p.) prior to a final 
i.c.v.  injection.  Results are plotted as the percentage of mice protected from 6 Hz (32 
mA) seizures.  No significant shift between the acute and repeated dose response curves 
was observed (n = 8-16 per dose per group). 
 





































ED50 and 95% confidence intervals following systemic or central administration of NAX-
5055 in acute or repeatedly dosed mice 
 
 
Treatment Group                  ED50 (mg/kg)       95% Confidence Interval 
 
I.P. administration 
 Acute        1.1              0.85 – 1.38   
 Repeated       8.8         7.05 – 10.75 
         
I.C.V. administration                      
 Acute           0.3             0.13 – 0.63 
 Repeated       1.25        0.36 – 4.98    
 
 
Treatment groups were defined by the route of administration (i.e., i.p. or i.c.v.) by which 
mice received NAX-5055 prior to testing in the 6 Hz (32 mA) model.  Within each group, 
mice are separated into those that received only one dose of NAX-5055 on the day of 
testing (acute) and those that received three once daily injections of NAX-5055 
(repeated) prior to the test day.  (See methods for details) 
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of free phosphate groups above background levels (Figure 3.6A).  In contrast, incubation 
of mdr1a and mdr1b with verapamil (60 µM), a known substrate for Pgp, resulted in 
increased phosphate accumulation above baseline levels; thereby confirming assay 
validity (Figure 3.6A).  Thus it seems unlikely that efflux transport of NAX-5055 




 Our initial objective for this study was to evaluate the effect of NAX-5055 on the 
rate of corneal kindling acquisition.  When NAX-5055 failed to affect kindling 
acquisition rate, we investigated the extent to which repeated systemic administration of 
NAX-5055 would affect its antiseizure efficacy.  It quickly became evident that the anti-
seizure potential of NAX-5055 was markedly reduced following repeated systemic 
administration.  As a result, the focus of this study shifted to understanding the potential 
pharmacokinetic and/or pharmacodynamic mechanism(s) that could account for this 
phenomenon. 
 When administered 1 hr prior to each corneal stimulation NAX-5055 (4 mg/kg, 
i.p.), failed to affect the rate of corneal kindling acquisition in mice (Figure 3.1).  The 
failure of NAX-5055 to exhibit any effect on kindling acquisition was surprising.  In 
previous studies, when galanin is overexpressed in the CNS a significant delay in the 
appearance of generalized stage 4/5 seizures in both mouse and rat hippocampal kindling 
models was observed (Kokaia et al., 2001; Kanter-Schlifke et al., 2007).  Further, galanin 
has been suggested to facilitate the inhibitory action of low-frequency stimulation on
  
 
Figure 3.6.  NAX-5055 is not a substrate for the blood brain barrier transporter p-glycoprotein. 
 
A.) No ATPase activity was observed following incubation of NAX-5055 with either mouse P-gp isomer mdr1a or mdr1b.  Results are 
plotted for the activity of ATPase vs. concentration of NAX-5055.  Calculated ATPase activity for all concentrations of NAX-5055 
was lower than those observed in the presence of buffer alone.  Assays were run in quadruplicate for each isoform.  (Inset). The p-
glycoprotein substrate verapamil (60 µM) was assayed in tandem with NAX-5055 as a positive control and displayed a consistent 
increase in ATPase activity in all assays (Paired t-test, *p < 0.05, **p < 0.01) 


































































kindling acquisition.  Low-frequency stimulation (1 Hz) of the perforant path inhibits the 
development of stage 4/5 seizures in rats (Mohammad-Zadeh et al., 2007).  When the 
non-specific galanin antagonist M35 was injected into the hilus during low-frequency 
stimulation this effect was attenuated, suggesting galanin is important for the anti-
kindling effects observed with low frequency stimulation (Sadegh et al., 2007).  In 
addition, NAX-5055 displays potent antiseizure activity against fully expressed mouse 
corneal kindled and rat hippocampal kindled seizures (White et al., 2009).  This activity 
suggests that NAX-5055 is capable of modulating neuronal circuits considered important 
for generating kindled seizures.  Considering that galanin displays anti-kindling activity 
and NAX-5055 can block fully kindled seizures; one possible explanation for the failure 
of NAX-5055 to modulate corneal kindling is that repeated administration reduces the 
efficacy of NAX-5055. 
 To investigate the effect of repeated NAX-5055 administration, mice were treated 
daily for three days with NAX-5055 (4 mg/kg, i.p.) in the absence of any stimulation.  
Following the 4th and final dose of NAX-5055 mice were tested for seizure protection in 
the 6 Hz psychomotor seizure model.  This dosing paradigm resulted in a marked 
reduction in antiseizure efficacy of NAX-5055 (Figure 3.2).  A similar response was 
observed in C57BL/6 mice in the 6 Hz model, suggesting this phenomenon is not strain 
specific (data not shown).  Further, in fully kindled mice, a reduction in seizure severity 
was observed following a single 4 mg/kg dose of NAX-5055.  However, this effect was 
rapidly attenuated with each additional NAX-5055 administration (Figure 3.3C), 
suggesting the observed reduction in NAX-5055 efficacy is not model specific.  Together 
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these studies support the hypothesis that the anti-seizure efficacy of NAX-5055 is 
reduced as a result of repeated systemic administration of an acutely efficacious dose. 
 To determine the contribution of the active Gal(1-13) fragment and the chemical 
modifications toward the decrease in NAX-5055 efficacy, we utilized a scrambled 
structural isomer 805-1 where amino acid residues Trp2 and Tyr9 were swapped 
maintaining the chemical modifications of NAX-5055.  These two amino acid residues 
are known to be critical for the binding of galanin with its receptors (Land et al., 1991; 
Kask et al., 1998; Lundström et al., 2005).  Binding studies with 805-1 confirm that this 
peptide lacks an interaction with galanin receptors (data not shown).  Further, when 
administered acutely, 805-1 is not anticonvulsant in the 6 Hz model (White et al., 2009).  
Once-daily systemic injections of 805-1 for 3 consecutive days did not negatively affect 
the efficacy of acutely administered NAX-5055 (4 mg/kg) in the 6 Hz test (Figure 3.3).  
This observation suggests that the modifications added to the active galanin fragment of 
NAX-5055 are most likely not responsible for the reduction in NAX-5055 efficacy 
observed in this study. 
 Although our results do not fulfill the clinical definition of drug-resistant epilepsy 
(Kwan et al., 2010a); we have used the hypotheses proposed to explain this phenomena to 
guide the design of studies aimed at elucidating the mechanism(s) underlying the 
observed reduction in efficacy following repeated NAX-5055 administration.  The two 
main hypotheses for drug-resistant epilepsy involve the pharmacodynamic mechanisms 
of decreased target availability and increased efflux transport (Kwan and Schachter, 
2011).  We have also considered a pharmacokinetic mechanism of increased peripheral 
metabolism of NAX-5055, discussed in Chapter 4. 
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 The target hypothesis of drug-resistant epilepsy postulates that there is an 
alteration in the sensitivity of cellular target(s) toward the activity of antiepileptic drugs 
as a result of chronic treatment (Remy and Beck, 2006).  Evidence supporting this 
hypothesis includes the alteration of sodium channel function in resected tissue from 
drug-resistant patients, polymorphisms in sodium channels, and alteration in GABAA 
receptor subunit composition (Remy et al., 2003; Kwan et al., 2008; Loup et al., 2009).  
G-protein coupled receptors are known to be subject to complex intracellular trafficking 
and down-regulation following repeated agonist exposure in neurons (Bernard et al., 
2006).  Following galanin exposure, both GalR1 and GalR2 receptors are internalized in 
immortalized cell lines (Wang et al., 1998b; Xia et al., 2005; 2008).  GalR1 receptors, the 
assumed primary target of NAX-5055, are further trafficked to lysosomes for 
degradation, thereby reducing their membrane expression (Xia et al., 2008).  Thus, 
central galanin receptor modulation is a likely hypothesis for the reduced efficacy of 
NAX-5055 following repeated administration. 
 We hypothesized that if central galanin receptors were altered due to a lack of 
availability or decreased sensitivity to NAX-5055, then the attenuated antiseizure activity 
would persist following central administration.  However, if central galanin receptors 
were unaltered by repeated systemic injection, then NAX-5055, when administered 
directly into the brain, should inhibit seizures in mice resistant to the systemic effects.  
We tested this hypothesis in both the 6 Hz psychomotor seizure model and the corneal 
kindled mouse.  In both partial seizure models, central administration of NAX-5055 was 
successful in blocking seizures in mice rendered resistant to the systemic effects of 4 
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mg/kg NAX-5055 (Figure 3.4).  This observation suggests that central galanin receptors 
are unaltered in mice resistnat to systemically administered NAX-5055. 
 Dose-response experiments were conducted to further test the observation that 
galanin receptors were unaltered by repeated dosing.  When all injections of NAX-5055 
were administered systemically, a significant rightward shift in the dose-response curve 
was observed.  In contrast, no significant shift in the dose response was observed when 
the final injection of NAX-5055 was administered directly into the lateral ventricles 
(Figure 3.5).  Together these data suggest that repeated systemic administration of NAX-
5055 results in a reduction in potency, but not efficacy; i.e., complete seizure control 
(maximum efficacy) could be obtained by increasing the administered dose.  In addition, 
the lack of a shift in the central administration, dose-response curve supports the 
conclusion that galanin receptors remain available following repeated systemic injections.  
Thus it seems unlikely that alteration in galanin receptor function can account for the 
reduced potency associated with repeated NAX-5055 administration. 
 The second hypothesis of drug-resistant epilepsy is the ‘transporter hypothesis’.  
This hypothesis proposes that drug resistance results from overexpression of multidrug 
efflux transporters within, or around, the epileptic focus (Remy and Beck, 2006; Kwan 
and Schachter, 2011).  We attempted to determine whether multidrug efflux transporters 
contributed to the reduced anti-seizure activity of NAX-5055 following repeated systemic 
administration.  This hypothesis is of particular interest in light of the decreased potency 
of NAX-5055 observed in dose-response studies.  An increase in efflux transport of 




 ATPase-binding cassette (ABC) transporters are a large family of transmembrane 
proteins that transport a wide range of substrates, including some antiseizure drugs, 
across cellular membranes (Luna-Tortós et al., 2008; Aronica et al., 2011; Kwan and 
Schachter, 2011).  The most extensively studied ABC transporter is P-glycoprotein, a key 
element in the blood brain barrier.  P-gp is expressed in capillary endothelial cells where 
it acts to transport xenobiotics out of the brain, thereby reducing the concentration of 
substrate drugs (Aronica et al., 2011; Kwan and Schachter, 2011).  In patients with drug-
resistant epilepsy, there is a large body of evidence demonstrating that P-pg expression is 
increased in brain capillaries.  In addition, aberrant expression of P-gp is observed on 
astrocytes that constitute the blood-brain barrier (Aronica et al., 2003; Kwan et al., 
2010b).  In the mouse, P-gp is encoded by two genes, mdr1a and mdr1b, and both are 
highly expressed at the blood brain barrier (Schinkel et al., 1994; Rizzi et al., 2002). It is 
of particular interest that P-gp has been shown to actively transport lipophilic drugs that 
would be predicted to cross membranes by passive diffusion (Löscher and Potschka, 
2005).  Thus it seems possible that NAX-5055 could enter the brain by passive diffusion, 
but still be subject to increased efflux transport via interaction with P-gp. 
 To evaluate any interaction between NAX-5055 and P-gp we utilized an in vitro 
substrate assay.  In this assay verapamil, a known P-gp substrate, increases ATPase 
activity in both isoforms of mouse P-gp (mdr1a & mdr1b).  In contrast, NAX-5055, at 
concentrations up to 300nM, failed to affect baseline ATPase activity (Figure 3.6).  Thus, 
NAX-5055 is unlikely to act as a substrate for Pgp. 
 Despite the inability of Pgp to transport NAX-5055, we cannot completely rule 
out the contribution of transporters to the reduced potency of NAX-5055.  Other ABC 
  
83 
transporters including the multidrug resistance-associate proteins and breast cancer 
resistance protein, as well as non-ABC transporters have also been implicated in drug 
resistance (Aronica et al., 2011) and may actively transport NAX-5055.  Additional work 
is necessary to determine if one or more of these transport systems is capable of 
regulating brain levels of NAX-5055. 
 A final hypothesis to explain the reduced potency of NAX-5055 observed 
following repeated systemic administration is an increase in peripheral metabolism of 
NAX-5055.  The most direct way to address this hypothesis is to measure brain and 
plasma concentrations of NAX-5055 following acute and repeated systemic 
administration.  However, despite considerable effort, we have been unable to reliably 
quantify whole brain concentrations of NAX-5055 utilizing analytical chemistry.  
However, preliminary work utilizing LC/MS/MS techniques demonstrated that NAX-
5055 is present in plasma samples of both acute and repeatedly treated mice one hour 
after systemic administration (data not shown).  These data suggest that NAX-5055 
remains intact following repeated systemic administration, but further work is required to 
quantitatively determine NAX-5055 concentrations. 
 To directly address the possibility of increased metabolism of NAX-5055 we 
assayed the response of peripheral galanin receptors following repeated systemic 
administration.  Galanin receptors are expressed on !-cells of the pancreas, and activation 
of these receptors has been shown to inhibit insulin release (Gregersen et al., 1991; 
McDonald et al., 1994; Barreto et al., 2011).  If NAX-5055 were subject to increased 
metabolism, we would expect to see an attenuation of the insulin response following 
repeated systemic administration.  There was no significant difference in insulin levels 
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following acute or repeated systemic NAX-5055 administration (see Chapter 4).  Thus, it 
seems unlikely that peripheral metabolism of NAX-5055 is directly responsible for the 
reduction in efficacy of NAX-5055 following repeated administration.   
 NAX-5055 could be inactivated once it crosses the blood brain barrier.  Galanin 
has been shown to be inactivated by endogenous peptidases or metalloproteasees within 
the brain (Bedecs et al., 1995).  These enzymes may directly target the active galanin 
fragment of NAX-5055, thereby inhibiting its interaction with galanin receptors.  
Although this mechanism warrants further study, it seems unlikely given the observation 
that the efficacy of NAX-5055 is unaltered following i.c.v. administration in repeatedly 
dosed mice.  In addition, anti-seizure activity has been observed in mice overexpressing 
galanin, suggesting that chronically high galanin levels within the CNS do not attenuate 
peptide activity (McCown, 2006). 
 The initial goal of this study was to determine the disease modifying potential of 
NAX-5055.  However, the focus of this study shifted to understanding the mechanism(s) 
of reduced NAX-5055 potency.  It is tempting to speculate that the failure of NAX-5055 
to affect kindling rate results from the shift in potency of NAX-5055 following repeated 
administration.  Future studies utilizing chronic i.c.v. administration of NAX-5055 in 
addition to in vitro assays will continue to evaluate the disease-modifying potential of 
galanin receptor activation. 
 In conclusion, we have shown that NAX-5055 is a systemically available galanin 
analog with potent acute antiseizure activity that is subject to rapid attenuation following 
repeated systemic administration.  Throughout the course of this study, we have shown 
that the reduced potency of NAX-5055 is not likely due to an alteration in galanin 
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receptor function, efflux transport by P-glycoprotein, or increased peripheral metabolism.  
As a result, it remains unclear what underlying mechanism(s) might account for the 
altered response to NAX-5055 observed in these studies.  However, this phenomenon 
offers an interesting model to increase our understanding of the regulation of galanin 
receptors and galanin-based analogs in vivo.  In addition, these studies will help direct the 
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THE SYNTHETIC GALANIN ANALOG, NAX-5055 INHIBITS  
INSULIN RELEASE AND INDUCES HYPERGLYCEMIA  




The neuropeptide galanin is widely expressed in both the central and peripheral 
nervous systems.  However there is limited understanding of how each galanin receptor 
(GalR1, 2, and 3) mediates the physiological activity of galanin in vivo.  To address this 
issue we have developed a systemically available, metabolically stable galanin analog, 
NAX-5055.  NAX-5055 displays a preference for GalR1 receptors and possesses a potent 
anticonvulsant activity in animal seizure and epilepsy models, suggesting that NAX-5055 
engages central galanin receptors.  To determine if NAX-5055 also modulates the activity 
of peripheral galanin receptors, we evaluated the effect of NAX-5055 on glucose and 
insulin levels, which can be regulated by galanin receptors located on pancreatic !-cells.  
Both acute and repeated systemic administration of NAX-5055 (4 mg/kg) significantly 
increased blood glucose levels in NAX-5055-treated mice compared to those observed in 
vehicle-treated mice.  No hyperglycemia was observed when amino acid residues in the 
active galanin fragment of NAX-5055, thought to critical for receptor binding, i.e., Trp2 
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and Tyr9, were reversed.  NAX-5055 also alters the physiological response to a glucose 
challenge in mice.  During a glucose tolerance test (GTT), mice administered either acute 
or repeated injections of NAX-5055 displayed impaired glucose handling and reduced 
insulin response to an acute glucose challenge.  Here we have shown that systemic 
administration of a centrally active GalR1-preferring galanin analog produces acute 
hyperglycemia and an inhibition of insulin release in vivo and that these effects are not 
attenuated following repeated administration.  NAX-5055 thus provides a powerful new 
pharmacological tool to further the understanding of function of peripheral galanin 




Galanin is a 29 (30 in humans) amino acid neuropeptide widely expressed 
throughout the central and peripheral nervous system with similar immunoreactivity in 
mice, rats, and humans (Tatemoto et al., 1983; Köhler and Chan-Palay, 1990; Lang et al., 
2007).  Immunohistochemical studies have shown that galanin colocalizes with a number 
of classical neurotransmitters including glutamate, acetylcholine, serotonin, and GABA.  
Due to this broad expression pattern there has been diverse interest in the physiology of 
galanin.  To date galanin has been linked to the regulation of a number of neuronal 
functions including learning and memory, neuronal excitability, neuroprotection, and 
neuroendocrine regulation (Mazarati et al., 1998; Crawley, 2008; Hobson et al., 2008).  
The ability of galanin to modulate these physiological processes has led to an interest in 
the development of galanin-based therapies for a number of common pathological states 
including epilepsy, neuropathic pain, Alzheimer’s disease, and diabetes (Kask et al., 
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1997; Crawley, 2008; Lerner et al., 2008; Mechenthaler, 2008).  Galanin is known to 
bind to three distinct G-protein coupled receptors GalR1, GalR2, and GalR3 (Branchek et 
al., 2000).  Activation of either the GalR1 or GalR3 receptor results in a generally 
inhibitory action on the cell due to selective coupling to the inhibitory G-protein Gi 
(Parker et al., 1995).  In contrast, GalR2 receptors demonstrate a more complicated 
signaling cascade due to their interaction with a number of different G-proteins, including 
Gi and Gq/11, resulting in either a inhibitory or excitatory cellular response (Lang and 
Kofler, 2011).  The understanding of how each of these receptor subtypes contributes to 
the different physiological actions of galanin has been limited by the lack of systemically 
active, receptor-selective, galanin agonists and reliable galanin receptor antibodies (Lu 
and Bartfai, 2009; Robertson et al., 2011).  The development of better tools to investigate 
the effects of galanin both in vivo and in vitro will facilitate the potential development of 
neuropeptide-based therapeutics.   
Previous attempts to generate systemically active galanin agonists have produced 
two compounds: galmic and galnon (Saar et al., 2002; Bartfai et al., 2004).  However, 
both compounds were shown to interact with nongalanin receptors in the micromolar 
(µM) range thereby limiting their use as selective pharmacological tools (Lu et al., 2005).  
To address this issue, Bulaj and colleagues successfully designed a series of truncated 
galanin analogs in which nonessential amino acid residues are replaced by cationic and/or 
lipoamino acid residues (Bulaj et al., 2008).  One analog from this group, NAX-5055, 
was demonstrated to possess a 15-fold preference for GalR1 over GalR2 with nanomolar 
(nM) binding affinity in a time-resolved fluorescence binding assay (Bulaj et al., 2008; 
White et al., 2009).  
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Although the galaninergic system provides an interesting set of molecular targets 
for therapeutic development, modulation of this system is complicated by the broad 
physiological activity of the neuropeptide.  As a result, it is important to increase our 
understanding of how the different galanin receptor subtypes mediate the activity of 
galanin in a region and cell-type specific manor.  Of particular interest is the observation 
that GalR1 mRNA and immunoreactivity are highly expressed in both the ventral 
hippocampus and ! cells of the islets of Langerhans (Parker et al., 1995; Gustafson et al., 
1996; Jungnickel and Gundlach, 2005; Bhandari et al., 2010).  Within the ventral 
hippocampus galanin has been show to potently inhibit the release of neurotransmitters 
including acetylcholine and glutamate; thus suggesting a role for galanin in mediating 
cellular excitability in a region known to generate seizure activity (Zini et al., 1993; 
Mazarati et al., 2000; Yoshitake et al., 2011).  Increasing the concentration of central 
galanin through either direct injection or genetic overexpression delays acquisition of 
kindling and reduces the severity and duration of seizures following electronically or 
chemically evoked status epilepticus (Schlifke et al., 2006; Kanter-Schlifke et al., 2007).  
Further, we have recently shown that the GalR1 preferring analog NAX-5055 has potent 
anticonvulsant activity in a number of seizure and epilepsy animal models, suggesting 
that the GalR1 receptor is a promising molecular target for seizure control (White et al., 
2009).   
In the peripheral nervous system, galanin is known to regulate insulin secretion 
and blood glucose levels in may species including rodents and canines (McDonald et al., 
1994; Ahrén, 2000).  Galanin is expressed in sympathetic nerve terminals that innervate 
the endocrine pancreas and is colocalized with norepinephrine (Mei et al., 2006).  
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Stimulation of the mixed pancreatic nerve bundle results in the release of galanin at 
sufficient levels to inhibit insulin secretion in canines (Dunning and Taborsky, 1989).  
Further, galanin has been shown to reduce glucose-stimulated insulin release from 
cultured ! islet cells of the pancreas (Gregersen et al., 1991).  Consistent with the 
inhibition of insulin secretion, galanin infusion increases blood glucose levels in canines, 
but not in humans (Dunning and Taborsky, 1989; McDonald et al., 1994).  Although this 
hyperglycemic response could be mediated by the reduction of insulin secretion, there is 
additional evidence that glucagon levels are also increased following galanin infusion, 
which may play a role in the effect of galanin on circulating glucose levels (Dunning et 
al., 1986; Dunning and Taborsky, 1989).  Recent work investigating the expression levels 
of the galanin receptors on mouse !-cells showed detectable mRNA levels for all three 
receptors, with GalR1 demonstrating the highest expression levels (Barreto et al., 2011).  
However, it still remains unclear how the different galanin receptors mediate the galanin 
response in the endocrine pancreas.  Previous attempts to use galanin-based 
pharmacology to study the effects of galanin on the endocrine pancreas have failed due to 
lack of specificity and off-target effects of the available pharmacological tools galnon and 
galmic (Quynh et al., 2005). 
In this study we sought to determine if targeting GalR1 receptors with the GalR1-
preferring agonist NAX-5055 would affect glucose and insulin regulation at doses that 













 Adult male CF-1 mice weighing at least 18g (Charles River, Kingston, WA) were 
used for all experiments in this study.  Animals were housed in a temperature-, humidity-, 
and light-controlled (12 hr light:dark cycle) facility.  For all studies not involving a food 
restriction, mice were group-housed and provided free access to food (LabDiet) and 
water.  For studies involving a fast, mice were initially group-housed and given full 
access to food and water until the beginning of the fasting period.  At the beginning of the 
fasting period mice were housed individually and food restricted for 6 hr.  During the 
fast, mice were allowed free access to water.  All experimental procedures were 
performed in accordance with the guidelines established by the National Institutes of 
Health and received approval from the University of Utah’s Animal Care and Use 
Committee.  At the completion of all experimental procedures mice were humanly 
sacrificed by CO2 asphyxiation. 
 !
Experimental Design and Dosing Regimen !"#$%&'#!(#)&*+!,+'!"-#$,-,%&.+! !
The galanin analog NAX-5055 was originally designed and synthesized at the 
University of Utah as previously described (Bulaj et al., 2008), and later synthesized in 
bulk by NeoMPS (San Diego, CA).  An inactive scrambled analog of NAX-5055, i.e. 
805-1 in which Tyr2 and Trp9 were reversed, was also designed and synthesized at the 
University of Utah.  Solutions were prepared by dissolving synthesized peptides in 0.9% 
saline containing 1% Tween 20 (Sigma-Aldrich, St. Louis, MO).  Solutions were made 
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fresh daily.  Prior to each experiment, peptide concentration was confirmed by UV 
absorbance of tyrosine and tryptophan residues (Cary 50 Bio UV Spectrophotometer, 
Varian).  Dosing solutions containing peptide were administered to mice via 
intraperitoneal (i.p.) injection in a volume of 0.01 mL/g body weight.   
For all studies mice were randomly selected from their home cage and placed into 
experimental groups with no intentional bias.  Mice were removed from the colony, 
weighed, treated, and returned to the colony (in their home cage) or sacrificed between 
the hours of 8:00 AM and 5:00 PM.  For the multiple dose experiments mice were 
administered a single i.p. injection of either NAX-5055 (4 mg/kg), 805-1 (4 mg/kg) or 
vehicle (0.9% saline with 1% Tween 20) once daily for 4 consecutive days.  Whether 
peptide or vehicle was injected each day was dependent on the randomly assigned 
experimental group as described below.  Glucose and/or insulin levels were obtained one 
hour post-peptide injection, corresponding to the time to peak effect (TPE) for 
anticonvulsant activity (Bulaj et al., 2008). 
 
 
Repeated Administration of NAX-5055 and 805-1. 
 
In experiments comparing repeated treatment with either NAX-5055 or 805-1, 
mice were split into one of four treatment groups (n = 8, per group).  Group 1 (vehicle) 
mice received vehicle for all 4 days.  Group 2 (acute NAX-5055) mice received vehicle 
for the first 3 days followed by a single injection of NAX-5055 on the 4th day.  Group 3 
(repeated NAX-5055) mice received NAX-5055 for all 4 days.  Group 4 (805-1) mice 
were treated with 805-1 for the first 3 days followed by a single injection of NAX-5055 
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on the 4th day.  One hour after the last injection on day 4 glucose levels were obtained for 
all animals in all four groups. 
 
 
Acute and Repeated Administration of NAX-5055 
 
In experiments comparing the effect of acute or repeated treatment with NAX-
5055 mice were split into one of three groups.  Group 1 (vehicle) mice were administered 
vehicle for all 4 days.  Group 2 (acute NAX-5055) mice were administered vehicle for 
the first 3 days followed by a single injection of NAX-5055 on the 4th day.  Group 3 
(repeated NAX-5055) mice were administered NAX-5055 for all 4 days.  Mice treated 
with this dosing regimen were also subjected to a glucose tolerance test (described in 
detail below) wherein glucose and/or insulin levels were determined.  Given the amount 
of blood (approximately 200 µL per animal) that was required to obtain enough plasma to 
run duplicate samples using an insulin ELISA, blood samples were taken from different 
sets of mice and then pooled for insulin determination.  For determination of glucose 
levels, six animals were used in the vehicle and acute NAX-5055 treatment groups, eight 
animals were used from the repeated NAX-5055 treatment group and all animals were 
subjected to a GTT on the same day.  For determination of insulin levels, 16 mice per 
group were used.  Two separate glucose tolerance tests were conducted using eight 
animals per group per day.  There was no significant difference in insulin levels from 









Glucose and Insulin Measurements 
 
Blood samples were obtained from a cut made approximately 1 cm from the tip of 
the tail in gently restrained mice.  Glucose levels were measured using a Bayer Contour 
blood glucose meter (9545C, Tarrytown, NY) and Contour blood glucose test strips 
(7098C, Tarrytown, NY).  Measurements were made directly from the tail clip.  Insulin 
levels were measured from plasma.  Blood was collected from tail clips in lithium 
heparin Microtainer® tubes (Becton Dickinson), and immediately placed on wet ice until 
samples from all animals had been collected.  Blood samples were spun using a tabletop 
microcentrifuge (Labnet Spectrafuge™ 16M) for 5 min at 14,000 rpm.  Plasma was 
removed from the samples and frozen at -80 °C until insulin levels could be determined 
using Ultra sensitive mouse insulin ELISA kits (Crystal Chem, Inc., Chicago, IL).  




Glucose Tolerance Test 
 
For the glucose tolerance test (GTT) mice were fasted for 6 hrs prior to the start of 
the test.  As determined by their assigned treatment group, mice were given their fourth 
and final injection of either vehicle or NAX-5055 five hours after the start of the food fast 
and 1hr prior to the beginning to the test, so that the GTT would begin at the TPE for 
NAX-5055 (i.e., 1 hr).  At the beginning of the GTT (corresponding to time point 0), 
blood samples were collected for insulin measurement and glucose level determination.  
Immediately following the collection of these samples mice were administered a 1 g/kg 
i.p. injection of D-glucose (Sigma-Aldrich, St. Louis, MO).  Glucose levels were sampled 
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at 0, 5, 15, 30, 60, and 120 min post glucose injection.  For insulin level determination, 
blood samples were drawn at 0, 15, 30, and 60 min postglucose injection (Figure 4.1).  




All data and results are reported as means ± standard error of the mean (SEM).  
Statistical significance was determined by unpaired t-tests when comparing only two 
groups (Figure 4.2) and one-way ANOVA when comparing three or more groups 
(Figures 4.3 & 4.4).  To determine significance between groups involving multiple 
comparisons, Bonferroni post hoc tests were used to compare significance between all 
groups and Dunetts post hoc tests were used to compare experimental treatments to 
vehicle controls.  Area under the curve (AUC) was calculated, using the trapezoid rule, 
for individual curves generated during the time course of the GTT for both glucose and 
insulin measurements.  A one-way ANOVA of the calculated AUC values was used to 
determine any significant differences.  All statistics were done using GraphPad Prism 






Glucose Response to NAX-5055 
 
We have previously demonstrated that a 4 mg/kg systemic injection of the GalR1 
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psychomotor seizure model with minimal motor impairment (Bulaj et al., 2008; White et 
al., 2009).  To determine if this anticonvulsant dose of NAX-5055 would also elicit a 
physiological response from peripheral pancreatic galanin receptors we measured blood 
glucose levels 1hr after a single systemic injection of vehicle or NAX-5055 (4 mg/kg).  
Mice administered NAX-5055 displayed increased glucose levels (mean ± SEM: vehicle, 
188.2 ± 5.3 mg/dL; NAX-5055, 312.9 ± 27.9 mg/dL, p < 0.0001; n=14, per group) 
(Figure 4.2A). 
 To determine if the observed increase in glucose levels following systemic 
administration resulted from the interaction of the active Gal(1-13) fragment of NAX-
5055 with galanin receptors, or as a side effect of the chemical modifications added to 
increase bioavailability we designed and synthesized a scrambled peptide version of 
NAX-5055; i.e., 805-1.  This peptide was designed with the residues Trp2 and Tyr9 
reversed.  The remaining 11 amino acids of the active fragment and other modifications 
remained unaltered.  These two amino acid residues are known to be critical for high 
affinity binding of galanin to its receptors (Land et al., 1991; Kask et al., 1998; 
Lundström et al., 2005).  Time-resolved fluorescent binding studies with 805-1 confirm 
that this peptide does not bind with high affinity to either GalR1 or GalR2 receptors (data 
not shown).  No significant increase in blood glucose levels was observed in mice treated 
with 805-1 (4 mg/kg) 1 hr postadministration (mean ± SEM: vehicle, 169.8 ± 8.3 mg/dL; 
805-1, 164.5 ± 14.6 mg/dL, p = 0.76; n = 4 per group) (Figure 4.2B).  These results 
suggest the direct interaction of the active galanin fragment of NAX-5055 with the 
pancreatic galanin receptors is critical for eliciting the hyperglycemic effect observed in 




Figure 4.2. Systemic administration of the galanin analog NAX-5055 produces 
hyperglycemia.   
 
A.) Mice were given a single i.p. injection of NAX-5055 (4 mg/kg) and glucose levels 
were measured 1 hr after injection.  Treated mice showed a significant increase in blood 
glucose levels (unpaired t-test, ***p < 0.001, n = 8).   
 
B.) Mice were given a single i.p. injection of the inactive analog 805-1 (4 mg/kg), which 
displays no affinity for the galanin receptors GalR1 or GalR2.  805-1 did not produce a 
significant change in blood glucose levels 1 hr after i.p. injection (unpaired t-test, p > 


































Glucose Response to Repeated NAX-5055 
 
Both the GalR1 and GalR2 receptors have been shown to rapidly internalize following 
chronic agonist exposure in vitro.  Following internalization, GalR1 receptors are 
transported to lysosomes for degradation, resulting in decreased membrane expression 
(Wang et al., 1998; Xia et al., 2005; 2008).  To determine if repeated activation of 
galanin receptors in vivo would attenuate the observed hyperglycemia, we repeatedly 
dosed mice with NAX-5055 and evaluated blood glucose levels one hour after the last 
challenge dose.  For this study, four treatment groups were employed as outlined in 
Figure 4.3A and described in detail in the Methods section.  Mice given either a single or 
repeated administration of NAX-5055 showed elevated glucose levels compared to 
vehicle-treated mice (mean ± SEM: vehicle = 157.5 ± 6.5 mg/dL; acute NAX-5055 = 
353.5 ± 39.9 mg/dL; repeated NAX-5055 = 378.0 ± 20.8 mg/dL, p < 0.0001, n = 8 per 
group) (Figure 4.3B).  In addition, mice repeatedly treated with 805-1 followed by a 
single administration of NAX-5055 also displayed elevated glucose levels compared to 
vehicle treated mice (mean ± SEM: vehicle = 157.5 ± 6.5 mg/dL; 805-1 = 297.5 ± 39.0 
mg/dL, n = 8, per group) (Figure 4.3B). There was no significant difference between the 
glucose levels of the acute, repeated or scrambled peptide treatment groups (p > 0.5) 
(Figure 4.3B).  These data suggest that repeated exposure of pancreatic galanin receptors 
to the agonist NAX-5055 in vivo does not diminish the hyperglycemia associated with 






Figure 4.3.  Repeated treatment with NAX-5055 does not attenuate the hyperglycemic 
effect seen with NAX-5055.   
 
A) Schematic of the experimental design.   
 
B) Glucose levels following acute or repeated treatment with NAX-5055 or 805-1; 
groups described in detail in Methods.  All groups that received at least one injection of 
NAX-5055 showed a significant increase in blood glucose levels (one-way ANOVA, 
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Glucose Tolerance Test Following NAX-5055 Administration 
 
Based on the robust hyperglycemia induced by NAX-5055 under basal 
conditions, we sought to further investigate the effect of NAX-5055 on glucose and 
insulin levels in response to a glucose tolerance test (GTT).  Both acute and repeated 
administration studies were run in tandem to determine if repeated receptor activation 
would influence regulation of glucose and insulin levels.  For this study three treatment 
groups were employed as outlined in Figure 2.4A and as described in detail in the 
Methods section.  
We first measured glucose levels in mice treated with either acute or repeated 
doses of NAX-5055.  At the 0 min time point (immediately before glucose injection) both 
the acute and repeatedly treated mice displayed elevated glucose levels compared to 
vehicle controls; however a significant differnce was only observed between the vehicle 
and repeated treatment groups (mean ± SEM: vehicle = 152.8 ± 5.3 mg/dL; acute = 215.5 
± 32.7 mg/dL; repeated = 290.8 ± 28.1 mg/dL, p = 0.0051) (Figure 4.4B).  All mice 
showed increased blood glucose levels following glucose injection, but varied in their 
time to peak effect and the magnitude of the hyperglycemia observed.  For example, in 
vehicle-treated animals glucose levels peaked at 15 min after glucose injection and 
returned to baseline after 60 min.  However, in both the acute and repeated treatment 
group, glucose levels increased immediately after glucose injection, but did not reach 
peak levels until after 60 min (Figure 4.4B).  Total area under the curve of the glucose 
response was significantly increased for acute and repeated treatment groups compared to 
vehicle treated controls (p < 0.001).  No significant difference in glucose levels between 
mice subjected to acute or repeated dosing with NAX-5055 was observed (Figure 4.4C). 
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Figure 4.4. Mice given a single acute or repeated treatment with NAX-5055 show 
exaggerated hyperglycemia and decreased insulin secretion following a systemic glucose 
challenge.   
 
A) Schematic of the experimental design.   
 
B) Glucose levels in vehicle (n = 6), acute (n = 6), and repeatedly (n = 8) treated mice 
across the duration of the glucose tolerance test.   
 
C) AUC measurements for all groups demonstrate both acute and repeated treatment 
groups have significantly increased blood glucose levels compared to vehicle treated 
mice (One-way ANOVA of AUC, **p < 0.01, ***p < 0.001).   
 
D) Insulin levels in vehicle (n = 16), acute (n = 16), and repeatedly (n = 16) treated mice 
across the duration of the glucose tolerance test.   
 
E) AUC measurements for all groups demonstrate both acute and repeated treatment 
groups have significantly decreased plasma insulin levels compared to vehicle treated 
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 Given that the direct action of galanin on glucose regulation is proposed to be 
related to its ability to inhibit insulin release, we measured insulin levels following either 
acute or repeated treatment with NAX-5055.  At time point 0 in the GTT (immediately 
before glucose injection) both the acute and repeated treatment groups displayed 
significantly decreased insulin levels compared to vehicle controls (mean ± SEM: vehicle 
= 1.4 ± 0.19 ng/mL; acute = 0.22 ± 0.08 ng/mL; repeated = 0.58 ± 0.09 ng/mL, p < 0.001, 
n = 16 per group) (Figure 4.4D).  Following glucose injection, only the vehicle treated 
animals showed any glucose-induced increase in insulin levels; insulin levels peaked at 
15 min and rapidly returned to preglucose injection levels.  The total area under the 
insulin response curve demonstrates a significant decrease in insulin release for both the 
acute and repeated treatment groups compared to vehicle treated controls (p < 0.001) 
(Figure 4.4E).  In contrast, there was no significant difference between acute and repeated 





 This study is the first to demonstrate that a systemically available GalR1-
preferring galanin analog can regulate glucose and insulin levels in vivo, in a manner 
similar to that proposed for endogenous galanin (McDonald et al., 1994; Ahrén, 2000).  
Acute administration of NAX-5055 resulted in a significant increase in glucose levels 
under both basal conditions and following an acute glucose challenge.  In contrast, 
insulin levels were significantly reduced following acute NAX-5055 administration under 
basal conditions.  Furthermore insulin levels of NAX-5055 treated mice did not fluctuate 




glucose and insulin levels persisted following a 4-day repeated dosing regimen.  This 
effect is likely mediated by the direct interaction of NAX-5055 with pancreatic galanin 
receptors. 
 The observed increase in basal glucose levels following a single administration of 
NAX-5055 is consistent with previous studies showing hyperglycemia in canine, rat and 
mouse following intravenous galanin infusion and stimulation of mixed pancreatic 
nerves, which is associated with galanin release (McDonald et al., 1985; Manabe et al., 
1986; Lindskog and Ahrén, 1987).  The effect of galanin on glucose levels has largely 
been attributed to the inhibition of insulin release from !-cells of the pancreas (Gregersen 
et al., 1991).  Our results support this hypothesis as insulin levels are also significantly 
reduced following acute NAX-5055 administration.  Some suggested mechanisms for the 
inhibition of insulin by galanin include opening of ATP–sensitive K+ channels, reduction 
in cAMP levels by inhibion of adenylyl cyclase and direct inhibition of exocytosis (de 
Weille et al., 1988; Sharp, 1996).  Activation of ATP-sensitive K+ channels and 
inhibition of cAMP levels has also been seen in the central nervous system following 
galanin receptor activation and is suggested to play a role in inhibiting neurotransmitter 
release (Zini et al., 1993; Hawes et al., 2006).  It should be noted that intravenous galanin 
administration not only affects insulin secretion, but it may also increase glucagon levels 
as seen in both the canine and mouse, but not in rat (Dunning et al., 1986; Lindskog and 
Ahrén, 1987; Silvestre et al., 1987).  During the GTT, both acute and repeated NAX-
5055 treated mice showed increased glucose levels; however those receiving repeated 
NAX-5055 injections displayed higher glucose levels, particularly at the 15 and 30 min 




tempting to speculate that the robust increase in glucose following administration of 
NAX-5055 may result from both an inhibition of insulin as well as an increase in 
glucagon secretion.  In addition, mRNA expression levels for the GalR1 receptor are the 
highest of all three galanin receptors on the ! cells (Barreto et al., 2009); thus direct 
activation of this receptor by NAX-5055 suggests that GalR1 may play a primary role in 
mediating the effects of galanin on glucose and insulin levels. 
 The finding that there is no significant attenuation of the hyperglycemic response 
to NAX-5055 following repeated treatment is particularly interesting.  In the past, these 
types of studies have been difficult to perform with native neuropeptides in vivo because 
of their propensity for rapid degradation following systemic administration (Bulaj et al., 
2008).  Work with immortalized cell lines in vitro has suggested that both GalR1 and 
GalR2 receptors are prone to internalization following prolonged agonist exposure (Wang 
et al., 1998; Xia et al., 2004; 2008).  Further, internalized GalR1 receptors have been 
shown to be trafficked to lysosomes for degradation and GalR1 activation-dependent 
inhibition of cAMP has been suggested to decrease receptor expression (Hawes et al., 
2006; Xia et al., 2008).  However, in our in vivo studies with mice, the hyperglycemic 
response elicited with single administration of NAX-5055 showed no attenuation to the 
response seen following four days of repeated dosing.  These results suggest that 
peripheral galanin receptors are responsive to NAX-5055 following both acute and 
repeated exposure.  This activity is dependent on the interaction of NAX-5055 with 
galanin receptors given that repeated treatment with the scrambled analog 805-1, which 
does not bind with galanin receptors, did not modify the NAX-5055-induced 




repeated treatment with this peptide would directly affect glucose levels.  However, we 
have shown that 805-1 has no effect on glucose levels following acute administration and 
that repeated administration does not attenuate or exaggerate the hyperglycemic response 
associated with acute NAX-5055 administration.  Thus, it seems likely that repeated 
treatment with 805-1 would have no effect on glucose levels following repeated 
administration.   
 C57/Bl6J mice are often used to test the activity of compounds in the glucose 
tolerance test (Dunning et al., 1986; Zorrilla et al., 2007).  For this study we chose to use 
the CF-1 mouse in order to directly relate our findings to the anticonvulsant studies that 
we have previously conducted with NAX-5055 using this mouse strain (Bulaj et al., 
2008).  Similar to work done with the C57Bl6J mice, glucose administration in vehicle-
treated CF-1 mice elevated glucose and insulin levels rapidly; i.e., both peaked within 15 
min of glucose injection.  Both glucose and insulin levels returned to baseline levels by 
the completion of the test, confirming glucose sensitivity in this strain of mice.  In 
contrast, the glucose tolerance test conducted in the acutely and repeatedly treated NAX-
5055 mice demonstrated an altered response to the glucose challenge, consistent with 
previous GTT studies with native galanin (Dunning et al., 1986; Lindskog and Ahrén, 
1987).  The proposed mechanism of galanin in this test is the inhibition of insulin release.  
Here we have shown that NAX-5055 completely abolishes any glucose stimulated 
increase in insulin release for the duration of the test.  These observations suggest that 
NAX-5055 is an effective and potent inhibitor of insulin release in mice.  Although not 
statistically significant, the insulin levels observed following repeated treatment are 




slight tolerance to the inhibition of insulin release following repeated treatment with 
NAX-5055; however, further study is required to fully test this hypothesis. 
 The altered response to the glucose challenge following both acute and repeated 
NAX-5055 treatment is evident in the persistent increase in blood glucose levels and lack 
of insulin response following systemic glucose injection.  These findings are consistent 
with other studies showing galanin-induced glucose insensitivity (Ahrén and Lindskog, 
1992).  However, studies with either the galanin knockout mouse or GalR1 knockout 
mouse have also shown glucose insensitivity in a glucose tolerance test; i.e., knockout 
mice displayed impaired insulin secretion and glucose disposal (Ahrén et al., 2004; 
Zorrilla et al., 2007).   It remains unclear why this conflicting response occurs in these 
knockout strains.  One possibility is that galanin and/or the GalR1 receptor has an 
important role in the development of normal !-cell innervations or physiological function 
and thus normal cellular activity is compromised in the presence of the mutation.  A 
second possibility is that there are compensatory changes in galanin receptor number or 
other neuropeptide systems that may alter the response of !-cells to either galanin or 
glucose stimulation. 
 The hyperglycemia and inhibition of insulin release observed with NAX-5055 
raises concerns about the use of systemically active GalR1 preferring analogs for the 
treatment of neurological diseases in humans.  However, the effect of galanin on glucose 
and insulin levels in humans is inconsistent.  Similar to mice and dogs, humans express 
galanin in nerves innervating islet cells of the pancreas (Ahrén et al., 1991).  Infusion of 
human galanin during an oral glucose test in normal humans at doses shown to inhibit 




al., 1994).  However, in isolated human islets cells, infusion of porcine galanin 
significantly inhibited insulin release (Ahrén et al., 1991).  These diffences between in 
vivo and in vitro studies suggest that galanin’s regulation of insulin levels in humans may 
extend beyond the its direct effects on !-cells. 
The regulation of galanin expression is also directly affected by glucose in 
humans, such that circulating galanin levels positively correlate with increased glucose 
levels in a oral glucose test in healthy controls (Legakis et al., 2007).  Further, adults with 
type-2 diabetes and children with type-1 diabetes mellitus show elevated galanin (Celi et 
al., 2005; Legakis et al., 2005).  Thus there is not a direct correlation between the effects 
of galanin in animal model systems and in humans suggesting the effects we report here 
for NAX-5055 may not translate to humans.  In addition, it is still unclear how each 
galanin receptor mediates the effects of galanin on !-cell function.  The data shown here 
suggest that GalR1 is directly involved in regulating glucose and insulin levels; however, 
a non-GalR1 agonist may not display this same effect.  Indeed preliminary evidence with 
GalR2-preferring analogs in our lab demonstrates that targeting this receptor results in 
anticonvulsant activity without negatively affecting blood glucose levels (unpublished 
results).  Increased understanding of the role of each galanin receptor in the different 
physiological functions of galanin in both the peripheral and central nervous systems will 
help mitigate concerns about the clinical use of galanin-based theraputics. 
 This study is the first to show that a GalR1-preferring galanin analog acts in the 
endocrine pancreas in a way similar to galanin infusions in vitro.  Evidence that !-cells 
contain mRNA to encode all three galanin receptor subtypes enhances the need to further 




of galanin in vivo.  In conclusion, we have shown here that the GalR1 receptor agonist 
NAX-5055 is a potent regulator of both glucose and insulin in the mouse under basal and 
glucose-stimulated conditions.  NAX-5055 thus provides the scientific community with a 
useful pharmacological tool to increase our understanding of how the different galanin 
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Background and Significance 
 
 Epilepsy is one of the most common neurological disorders, affecting patients 
with no clear bias for age, gender, or socioeconomic status (Institute of Medicine, 2012).  
The myriad of epilepsy syndromes can manifest in various behavioral phenotypes; 
however, all patients share the same clinical hallmark of recurrent spontaneous seizures.  
Although 70% of epilepsy patients achieve seizure freedom with pharmacological 
treatment, the remaining 30% of patients demonstrate resistantance to pharmacological 
intervention (Stephen and Brodie, 2012).  It has been proposed that in order to effectively 
treat drug-resistant patients, future research must focus attention on the modulation of the 
pathological brain via novel molecular targets (Löscher and Schmidt, 2011). 
 Potential novel targets for the treatment of epilepsy include the neuropeptide 
galanin and its receptors.  Galanin expression is increased following seizure activity 
(Mazarati et al., 1998; Wilson et al., 2005) and exogenous injection produces antiseizure 
activity in a number of animal models (Lerner et al., 2008).  However, our understanding 
of the antiseizure properties of galanin has been limited by the lack of receptor-selective 
and systemically available pharmacological tools.  The work presented in this dissertation 




Although the results of our studies identify properties of NAX-5055 that minimize its 
therapeutic potential as an antiseizure medication, NAX-5055 remains a useful 
experimental tool to study the function of galanin receptors.  In addition, the approach 
and assays discussed in this dissertation provide a useful outline for the future 
development of neuropeptide-based theraputics. 
 
 
Summary and Conclusions 
 
The studies described in Chapter 2 were aimed at elucidating the mechanism of 
action of NAX-5055 in the hippocampus.  We hypothesized that NAX-5055, like many 
other neuropeptides, would reduce hippocampal excitability by inhibiting presynaptic 
neurotransmitter release (Tallent, 2008).  Our studies demonstrate that NAX-5055 
increases the inter-event interval of mEPSCs in mouse organotypic hippocampal slice 
cultures (OHSC) without affecting the amplitude of these events in CA3 pyramidal 
neurons.  These results suggest that NAX-5055 reduces the probability of presynaptic 
glutamate release onto CA3 pyramidal cells.  This is a particularly interesting finding 
given the preference of NAX-5055 for GalR1 receptors.  Confirmation of this finding in 
future studies would provide the first evidence of a GalR1-mediated presynaptic 
mechanism of action for galanin. 
 Acute systemic administration of NAX-5055 displays potent anti-seizure efficacy 
in a battery of seizure and epilepsy animal models (Bulaj et al., 2008; White et al., 2009).  
The initial aim of this dissertation was to evaluate the disease modifying potential of 
NAX-5055 in the corneal kindled mouse.  This aim was based on the observation that 




4/5 seizures in mouse and rat kindling models (Kokaia et al., 2001; Kanter-Schlifke et al., 
2007).  As described in Chapter 3, NAX-5055 had no effect on the corneal kindling 
acquisition rate in mice.  This was an unexpected finding given the previous literature 
and led to the hypothesis that the failure of NAX-5055 to alter kindling acquisition could 
result from a reduction in the efficacy or potency of NAX-5055 following repeated 
systemic administration.  To test this hypothesis, mice were administered systemic 
injections of NAX-5055 (4 mg/kg) once daily for four consecutive days and then tested in 
the 6Hz psychomotor seizure model.  The antiseizure efficacy of NAX-5055 was 
dramatically reduced following repeated systemic injection, suggesting a reduction in the 
efficacy of NAX-5055 at this dose.  Similar effects were observed in C57BL/6J mice and 
fully kindled CF-1 mice, suggesting this effect is not strain or model specific. 
 The results of these repeated dosing experiments shifted the focus of this 
dissertation work to studies that aimed to define the mechanism(s) responsible for the 
reduced efficacy of NAX-5055 observed following multiple doses.  I proposed three 
independent hypotheses that could account for the observation of this phenomenon.  The 
first hypothesis is the “target hypothesis,” which proposes that drug targerts are altered 
following repeated exposure.  The second hypothesis is the “transport hypothesis,” which 
proposes that drug transport is altered following repeated exposure.  Both of these 
hypotheses have been found to explain the development of drug-resistance in epilepsy 
patients (Remy and Beck, 2006; Kwan and Schachter, 2011).  The third hypothesis, 
discussed in Chapter 4, proposes that peripheral metabolism of NAX-5055 is increased, 






The Target Hypothesis 
 The “target hypothesis” of drug-resistant epilepsy proposes that alterations to the 
cellular targets of antiseizure drugs results in a reduction of their sensitivity to 
pharmacological engagement (Remy and Beck, 2006; Kwan and Schachter, 2011).  A 
clinical example supporting this hypothesis comes from studies conducted with 
hippocampi resected from patients resistant to the antiseizure effects of carbamazepine.  
Electrophysiological recordings demonstrated a lack of use-dependent block of Na+ 
channels normally observed in the presence of carbamazepine as well as an inability to 
block induced seizure activity in the slice (Remy et al., 2003). 
 The target hypothesis appeared viable to explain the reduction in efficacy of 
NAX-5055; particularly given that galanin receptors are prone to internalization 
following agonist exposure in vitro (Wang et al., 1998; Xia et al., 2005; 2008).  Further, 
the internalization and trafficking of peptide G-protein-coupled receptors has been 
extensively studied, and is commonly proposed as a mechanism to explain observed 
reductions in drug efficacy (Bernard et al., 2006; Kelly et al., 2008).  To evaluate the 
reduction in efficacy of NAX-5055 we generated dose response curves for mice given 
either acute or repeated doses of NAX-5055.  When all doses were administered 
systemically, we observed a significant rightward shift in the dose-response curve for 
repeatedly treated mice (Figure 3.5).  This response shows that galanin receptors are 
available for interaction with NAX-5055 following repeated treatment, but increased 
concentrations are required to achieve the same efficacy.  This suggests a decrease in 
potency of NAX-5055 following repeated systemic injection.  In contrast, no significant 




administered directly into the ventricular space of the brain.  This observation is 
consistent with the hypothesis that there is no change in galanin receptor availability 
following repeated systemic injection. 
 
 
The Transport Hypothesis 
The “transport hypothesis” of drug-resistant epilepsy proposes that an increase in 
the expression of drug-efflux transporters results in a reduced concentration of a anti-
seizure drug in the brain (Remy and Beck, 2006; Kwan and Schachter, 2011).  Evidence 
for this hypothesis comes from studies showing that the ATP-binding cassette transporter 
p-glycoprotein is upregulated in the capillaries of hippocampal tissue resected from 
temporal lobe epilepsy patients (Kwan et al., 2010).  In addition, in vitro studies have 
shown that a number of antiseizure drugs can act as substrates for p-glycoprotein (Tishler 
et al., 1995; Luna-Tortós et al., 2010).  To our knowledge, there is no known transport 
mechanism for galanin within the central nervous system.  However, NAX-5055 has a 
number of chemical modifications to its galanin core that could make it susceptible to 
active efflux transport.  To determine if efflux transport of NAX-5055 could account for 
the reduced potency of NAX-5055 observed following repeated systemic injection, we 
evaluated whether it could serve as a substrate for mouse p-glycoprotein.  In Chapter 3 
we show that NAX-5055 does not interact with either isoform (mdr1a and mdr1b) of 
mouse p-glycoprotein.  Thus, it seems unlikely that efflux transport through p-






Peripheral Metabolism of NAX-5055 
The third and final hypothesis evaluated in an effort to explain the reduced 
potency of NAX-5055 proposes that an increase in peripheral metabolism would reduce 
the amount of functional peptide available for interaction with galanin receptors.  The 
most direct approach to address this hypothesis would be to compare plasma and brain 
concentrations of NAX-5055 following acute and repeated systemic administration.  
However, we have not been able to determine brain or plasma levels of NAX-5055 using 
analytical chemistry techniques.  To circumvent this issue, we took an indirect approach 
and tested the activity of NAX-5055 on peripheral galanin receptors.  Galanin receptors 
are expressed on !-cells of the pancreas and activation of these receptors has been shown 
to inhibit insulin release (Tatemoto et al., 1983; Lindskog and Ahrén, 1987; Barreto et al., 
2011).  In Chapter 4 we show that NAX-5055 significantly reduces plasma 
concentrations of insulin following a single systemic administration.  There was no 
attenuation of this effect in mice subjected to repeated systemic NAX-5055 injections.  
The lack of attenuation in the insulin response suggests that NAX-5055 remains in an 
active form that can engage galanin receptors following repeated administration.  In 
summary, our studies were unable to describe a clear mechanism for the reduced potency 
of NAX-5055 following repeated systemic administration. 
 
 
Speculations and Future Directions 
 
 Throughout this dissertation work we have often made the assumption that NAX-
5055 exerts its activity largely through activation of the GalR1 receptor.  This assumption 




the GalR1 receptor over the GalR2 receptor (Bulaj et al., 2008).  However, NAX-5055 
maintains nanomolar affinity for GalR1 and GalR2; as such, NAX-5055 could engage 
either receptor subtype following systemic and/or central injection.  This is of particular 
relevance given that it is unclear what the levels of NAX-5055 are within the brain 
following systemic administration.  In an effort to test this assumption we have recently 
acquired and genotyped GalR1 knockout mice (GalR1-KO).  These mice display minimal 
physiological differences from wild-type mice; further, they show no alteration in the 
expression of GalR2 or GalR3 receptors (Jacoby et al., 2002; McColl et al., 2006; 
Schauwecker, 2010).  Evaluation of the anti-seizure activity of NAX-5055 in these mice 
will be essential in confirming if GalR1 is the functional molecular target of NAX-5055 
within the brain. 
 It will also be interesting to determine the seizure thresholds of GalR1-KO mice 
in acute behavioral seizure models.  To date, GalR1-KO mice have only been tested in 
status epilepticus (SE) models.  In these studies GalR1-KO mice demonstrate increased 
susceptibility to both perforant path- and Li-pilocarpine induced SE (Mazarati et al., 
2004).  We would hypothesize that GalR1-KO mice will display decreased seizure 
thresholds in mouse seizure and epilepsy models.  It is also tempting to speculate that 
GalR1-KO mice will display decreased seizure thresholds in the partial seizure models in 
which NAX-5055 displays anti-seizure activity (e.g., 6 Hz psychomotor seizure & the 
kindling models).  This observation would further support the hypothesis that the 
antiseizure efficacy of NAX-5055 is GalR1-dependent.  Together, positive results in 
these studies would provide further validation of the GalR1 receptor as a CNS target for 




 Changes in galanin receptor expression and function within the brain following 
repeated agonist exposure remains an interesting question that we are now well 
positioned to address.  To date galanin receptor regulation has only been studied in 
immortalized cell lines (Xia et al., 2005; 2008).  In the present work, when a challenge 
dose of NAX-5055 was administered into the lateral ventricle, dose-response experiments 
failed to conclusively demonstrate a difference in seizure protection between acute or 
repeatedly treated mice.  However, we were unable to reach 100% seizure protection with 
any dose of NAX-5055 administered intracerebroventricularly.  This observation could 
result from off-target effects at the higher doses of NAX-5055 that may limit our ability 
to directly determine the effect of galanin receptor activation on seizure susceptibility.  
As a result, it is unclear if the highest doses of NAX-5055 administered were sufficient to 
saturate all available galanin receptors.  Thus, it remains possible that there are subtle 
changes in central galanin receptors following repeated agonist administration that cannot 
be detected with this experimental approach.  Even small changes in the expression of G-
protein-coupled galanin receptors could have meaningful physiological effects due to the 
activation of robust intracellular signaling cascades. 
 One additional approach that could be employed to test for changes in central 
galanin receptor activity in vivo is to repeatedly deliver NAX-5055 directly to the brain 
via implanted cannula and osmotic pumps.  If galanin receptors are indeed unaltered by 
repeated agonist exposure we would hypothesize that, under these conditions, the 
antiseizure activity of NAX-5055 would be maintained for the duration of release from 
the implanted osmotic pumps.  This hypothesis is supported by the observation that the 




released by adeno-associated viral vectors (Haberman et al., 2003; McCown, 2006; Foti 
et al., 2009).  In contrast, studies in immortalized cell lines suggest galanin receptors are 
internalized following agonist exposure and that GalR1 receptors are rapidly degraded 
following internalization (Xia et al., 2005; 2008).  This discrepancy underlies the 
importance of testing receptor regulation using both in vivo and in vitro approaches 
(Koenig and Edwardson, 1996; Coutts et al., 2001). 
 To complement the proposed in vivo studies, we are developing an in vitro, time 
resolved fluorescence, saturation-binding assay utilizing europium-labeled galanin, 
specific for isolated brain tissue.  This assay will allow us to directly measure the 
concentration of galanin receptors in the hippocampus of mice subjected to either acute 
or repeated NAX-5055 injection.  Coincubation of tissue preparations with unlabeled 
galanin and Gal(2-11) will allow us to identify any alterations in the concentration of 
GalR1, compared to GalR2, following NAX-5055 treatment.  One caveat of this 
approach is that it does not allow us to distinguish cell type specificity, which could be 
achieved utilizing histological techniques.  Unfortunately, a number of commercially 
available galanin receptor antibodies have been found to lack specificity for their targets; 
thus limiting our ability to conduct histological studies (Lu and Bartfai, 2009).  
 The aforementioned binding studies will help to define whether there are any 
alterations in galanin receptor expression; however, additional studies would be required 
to evaluate potential changes to the function of these receptors.  In Chapter 2 we show 
that acute exposure of NAX-5055 may reduce hippocampal excitability by reducing 
presynaptic glutamate release onto CA3 pyramidal neurons.  Similar to the behavioral 




slices from GalR1-KO mice to determine if the observed effects of NAX-5055 are indeed 
GalR1-dependent. 
 We are also particularly interested in the effects repeated exposure of NAX-5055 
will have on the functional regulation of galanin receptors.  One advantage of using 
mouse OHSC is the ability to preincubate slices with NAX-5055 and then record whether 
the sensitivity of the receptors to NAX-5055 changes in response to continuious agonist 
exposure.  If the results of our central administration dose response curves are predictive, 
then there should be no change in NAX-5055-induced reduction of glutamate release.  
However, if galanin receptors are prone to agonist-induced modulation, then 
preincubation with NAX-5055 should attenuate the observed increase in inter-event 
interval of mEPSCs.  We hypothesize that this attenuation would result from galanin 
receptor internalization.  Expression of fluorescently tagged GalR1 receptors in OHSCs 
generated from GalR1-KO mice would allow us to optically track receptors following 
agonist exposure.  This approach would be the first to show a correlation between 
membrane galanin receptor expression and function in neurons. 
 The use of NAX-5055 along with other galanin receptor preferring analogs will 
also allow us to further elucidate the role of galanin receptors in regulating synaptic 
transmission.  The studies discussed in this dissertation focused on spontaneous 
glutamate release; however, galanin receptors are also likely to play important roles in the 
regulation of action potential mediated vesicular release within the hippocampus.  In 
myenteric neurons and the nucleus tractus solitarius galanin has been demonstrated to 




ganglion neurons demonstrated that galanin enhanced calcium currents via a GalR2-
dependent mechanism !8(9(:(3' ()' *+,-' .//;7.  These galanin receptor-mediated 
alterations in calcium concentrations would be expected to increase or decrease cell 
excitability and thus alter the probability of spontaneous and/or evoked vesicular release.  
Thus a further extension of the work presented in Chapter 2 would be to characterize the 
role of GalR1 and GalR2 in the spontaneous and evoked release of neurotransmitters 
within the hippocampal formation.  
 In addition to potential modification of galanin receptors, the transport hypothesis 
remains a potential mechanism to explain the loss of potency observed with repeated 
NAX-5055 administration.  The dose-response curves following systemic injection 
suggest that the efficacy of NAX-5055 is unaltered, whereas potency is reduced.  This 
observation could be explained by altered transport mechanisms.  Transport of NAX-
5055 away from central galanin receptors would reduce the likelihood of ligand-receptor 
interaction.  This effect could be overcome by increasing the available concentration of 
NAX-5055 as a result of increasing the administered dose.  This speculation is 
confounded by the fact that there are no known transporters that target neuropeptides in 
the brain.  However, we cannot rule out the possibility that efflux transport of NAX-5055 
away from galanin receptors contributes to the observed reduction in antiseizure potency.  
Even though our studies suggest that NAX-5055 is not a substrate for p-glycoprotein, 
there is increasing evidence that additional transporters are modulated in epilepsy and 
that they may be involved in trafficking xenobiotics, such as NAX-5055.  These 
transporters include the breast cancer resistance protein (BCRP), the multi-drug 




Additional screening is thus necessary to determine if NAX-5055 can interact with any of 
these transporters.  If an interaction were identified, it would be of great interest to 
determine the site of interaction.  If the active galanin fragment of NAX-5055 is shown to 
interact with a transporter, this could open up a new line of research into the role of efflux 
transport in the central regulation of neuropeptides. 
 Finally, although not discussed in this dissertation, a side project in the laboratory 
has been investigating the interaction between NAX-5055 and the antiseizure drug 
levetiracetam (LEV).  Both drugs are thought to exert their antiseizure activity through 
presynaptic mechanisms (Lee et al., 2009).  Interestingly, they also display similar anti-
seizure profiles in animal seizure and epilepsy models; i.e., they both demonstrate potent 
activity in models of partial seizure (Klitgaard et al., 1998; Bulaj et al., 2008; White et al., 
2009).  Preliminary experiments have shown that these drugs display synergy when 
administered together.  In addition, repeated administration of NAX-5055 reduces the 
efficacy of LEV in the 6 Hz psychomotor seizure model.  It is tempting to speculate that 
these drugs share a similar mechanism; e.g., the regulation and response to intracellular 
Ca2+ (Lynch et al., 2004; Anselmi et al., 2009).  Study of the interaction of these two 
drugs could prove interesting in further understanding their mechanism of action.   
 Taken together, the studies presented in this dissertation were unable to provide a 
clear mechanism to explain the reduced potency of NAX-5055 following repeated 
systemic injection.  A summary of results with evidence for or against each hypothesis is 
outlined in Table 5.1.  Although we have not exhaustively ruled out any of the three 
proposed mechanisms, our studies support the conclusion that galanin receptor 




Table 5.1 Summary of potential mechanism(s) for reduced potency of NAX-5055 following multiple dosing 
 
 
Hypotheses for the reduced efficacy 
of NAX-5055 Support for the hypothesis Evidence against the hypothesis 
Target hypothesis of NAX-5055 
• GalR1 & GalR2 receptors are 
internalized following agonist exposure 
in vitro 
• Anti-seizure drugs demonstrate reduced 
efficacy in resected tissue from epileptic 
patients 
• Anti-seizure activity observed with galanin 
overexpression in mice and rats 
• NAX-5055 demonstrates a shift in potency, and 
not efficacy following repeated NAX-5055 
dosing 
• No difference in central administration dose 
response curves 
• No change in peripheral galanin receptor 
response to NAX-5055 following repeated 
administration 
Transport hypothesis of NAX-5055 
• Increased P-gp expression in resected 
tissue from epileptic patients 
• Anti-seizure drugs can act as substrates 
for P-gp 
• Shift in potency of NAX-5055 following 
repeated administration 
• NAX-5055 is not a substrate for mouse P-gp 
• No known mechanism for active transport of 
neuropeptides has been identified 
Increased Metabolism of NAX-5055 
• Peptides are prone to metabolism by 
peptidases 
• Unknown pharmacokinetics 
• Shift in potency of NAX-5055 following 
repeated administration 
• No difference in insulin levels following acute 




studies arguing against the target hypothesis are the repeated administration dose-
response studies where the last dose of NAX-5055 was administered peripherally or 
centrally, and the insulin release studies conducted after acute and repeated NAX-5055 
dosing.  If alterations in galanin receptors were involved in reducing the potency of 
NAX-5055 we would have expected an attenuated response following NAX-5055 
repeated dosing.  However, in both experiments no difference was observed in the 
behavioral or physiological response of mice that received either acute or repeated doses 
of NAX-5055.  This conclusion is supported by studies that showed antiseizure activity in 
the presence of constitutively released, overexpressed galanin in mice and rats 
(Haberman et al., 2003; McCown, 2006).  These studies suggest that central galanin 
receptors are functional in the presence of chronically elevated extracellular galanin 
levels.  The future studies proposed here will help further elucidate a clear mechanism(s) 
for the reduction in NAX-5055 potency in vivo.   
Although this work characterizes a number of unfavorable in vivo properties of 
NAX-5055 (e.g., hyperglycemia and reduced efficacy with repeated administration), it 
has also established a series of new methodologies in our laboratory.  These approaches 
will facilitate the future characterization of novel galanin analogs.  Our studies have 
centered on a GalR1-preferring compound; however additional GalR2-preferring 
compounds have also been designed and synthesized.  It is possible that GalR2-preferring 
compounds will display similar therapeutic potential without unfavorable side effects.  
Further, the ability to selectively target GalR1 or GalR2 receptors pharmacologically will 
enhance our understanding of the function of galanin and its receptors under basal and 
pathological conditions.  In conclusion, the development of an effective galanin-based 
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analog may prove useful for the treatment of epilepsy and other neurological disorders 
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